



Cite this: *Lab Chip*, 2022, 22, 1068

Oxygen control: the often overlooked but essential piece to create better *in vitro* systems

Valentina Palacio-Castañeda, ^a Niels Velthuijs, ^a
 Séverine Le Gac ^{*b} and Wouter P. R. Verdurmen ^{*a}

Variations in oxygen levels play key roles in numerous physiological and pathological processes, but are often not properly controlled in *in vitro* models, introducing a significant bias in experimental outcomes. Recent developments in microfluidic technology have introduced a paradigm shift by providing new opportunities to better mimic physiological and pathological conditions, which is achieved by both regulating and monitoring oxygen levels at the micrometre scale in miniaturized devices. In this review, we first introduce the nature and relevance of oxygen-dependent pathways in both physiological and pathological contexts. Subsequently, we discuss strategies to control oxygen in microfluidic devices, distinguishing between engineering approaches that operate at the device level during its fabrication and chemical approaches that involve the active perfusion of fluids oxygenated at a precise level or supplemented with oxygen-producing or oxygen-scavenging materials. In addition, we discuss readout approaches for monitoring oxygen levels at the cellular and tissue levels, focusing on electrochemical and optical detection schemes for high-resolution measurements directly on-chip. An overview of different applications in which microfluidic devices have been utilized to answer biological research questions is then provided. In the final section, we provide our vision for further technological refinements of oxygen-controlling devices and discuss how these devices can be employed to generate new fundamental insights regarding key scientific problems that call for emulating oxygen levels as encountered *in vivo*. We conclude by making the case that ultimately emulating physiological or pathological oxygen levels should become a standard feature in all *in vitro* cell, tissue, and organ models.

Received 9th July 2021,
 Accepted 20th January 2022

DOI: 10.1039/d1lc00603g

rsc.li/loc

Introduction

The tissue concentration of oxygen plays an important role in a variety of cellular processes in both normal and pathophysiological conditions, ranging from embryonic development to cancer as prototypical examples. Yet, in *in vitro* studies involving cells and tissues in classical systems, this role is often insufficiently taken into account, if not entirely neglected.¹ This leads to *in vitro* studies performed under non-reproducible, non-physiological conditions with well-documented unwanted effects on experimental outcomes.^{1,2} Therefore, it is essential to create and employ *in vitro* models that include active and accurate control of the oxygen tension. In recent years, engineers have been

addressing this challenge and designed numerous systems to regulate the oxygen tension in advanced 2D and 3D *in vitro* tissue models, with excellent potential for answering biological research questions. There is indeed increasing recognition of the importance of hypoxia in a wide variety of diseases and disorders as well as with respect to the action of many therapeutic agents. Examples range from the well-studied role of hypoxia in the progression of cancer³ to onset of fibrotic diseases⁴ and transient ischemic attacks (TIAs)⁵ or myocardial infarction,⁶ and from (cancer) immunotherapy⁷ to hypoxia-targeted drug delivery approaches.⁸ Furthermore, essentially all organs in the human body are exposed to different oxygen tensions and some to very low oxygen levels, and to gradients of oxygen across tissues. Hence, also non-pathological biological processes are impacted by low oxygen tension, including embryonic development,⁹ articular cartilage function,¹⁰ wound healing¹¹ and intestinal homeostasis,¹² all of which must be taken into account to create proper and fully functional *in vitro* models for human organs or organ functions.

Despite the immense potential of advanced engineered systems, researchers in life sciences are continuing to rely to

^a Department of Biochemistry, Radboud Institute for Molecular Life Sciences (RIMLS), Radboud University Medical Center, Geert Grooteplein 28, 6525 GA Nijmegen, The Netherlands. E-mail: Wouter.Verdurmen@radboudumc.nl; Tel: +31 24 36 14263

^b Applied Microfluidics for BioEngineering Research, MESA+ Institute for Nanotechnology & TechMed Centre, Organ-on-a-chip Centre, University of Twente, Postbus 217, 7500 AE Enschede, The Netherlands. E-mail: S.LeGac@utwente.nl; Tel: +31 53 489 2722



a large extent on classical methods for studying hypoxia such as large incubators with mostly non-physiologically high oxygen percentage, a variety of hypoxic chambers, and various animal models. Yet, all these systems, while they have proven value, also exhibit well-identified limitations and flaws. In 2D cultures growing in hypoxic chambers, the natural 3D environment of cells is not present, leading to many molecular and cellular adaptations and alterations.¹³ Furthermore, oxygen gradients cannot be incorporated in such systems. Hence, simple models in hypoxic chambers do not accurately or even properly mimic physiological processes happening *in vivo*. Crucially, the oxygen tension is not regulated at the micrometre scale, or in other words at the scale of the cellular model, but rather at the level of the system, risking the introduction of significant variations within the system. Animal models, on the contrary, are more complex and incorporate these physiological differences in oxygen tension and gradients thereof, but they tend to be expensive, suffer from a low throughput, are difficult to control or monitor at the molecular or cellular level and are generally not compatible with the study of dynamic biological processes in real-time. In addition, they are ethically problematic, subjected to strict regulation, like the 3 Rs legislation in the European Union and similar regulations in the US.^{14–16} Finally, there are significant worries regarding the extrapolation of results from animal models to the human situation due to essential physiological differences and the poor ability of rodents to model human diseases.¹⁷ Importantly, these differences include variations with respect to oxygen levels.^{18,19}

The advent of microfluidic technology is causing a paradigm shift. The inherent flaws of conventional 2D cellular and animal models can be overcome by exploiting novel technological advances for the (bio)engineering and application of microfabricated and microfluidic *in vitro* models. Those miniaturized models, that also encompass organ-on-chip devices,²⁰ offer new opportunities to engineer and control the cell microenvironment,²¹ which is notably brought about by the fact that surface phenomena dominate over bulk ones at the micrometre scale and that flows are laminar.²² The cell culture environment can be tuned at the micrometre scale, including a variety of physical and chemical parameters, such as gas tensions and temperatures. Similarly, stable gradients of those parameters can be created to better reproduce tissue-specific *in vivo* conditions.^{23,24}

The purpose of this review is to help build the bridge between engineers and life science researchers with respect to the use of advanced *in vitro* approaches with oxygen levels as found in physiological or pathological conditions. By informing about the advantages over alternative approaches and discussing main opportunities and key challenges for translational research, the potential of these systems for all-human disease models will be elucidated to life scientists and engineers alike. In this review, we will highlight several of the many roles of oxygen in health and disease(s), at the molecular, cellular, organ and systemic levels, and discuss

methods to control oxygen in microfluidic devices. We will then review studies that have implemented these methods and critically evaluate currently employed readout approaches. Finally, we share our vision for the future and report on main opportunities and key challenges that we have identified in the field.

Importance of oxygen in biological processes: from the molecular to the tissue level

Pathways involving hypoxia inducible factors (HIFs)

At the cellular level, several signalling pathways are involved in oxygen sensing, which differ in their sensitivity to the severity and duration of oxygen deprivation.²⁵ The most well-known pathway involves the hypoxia-inducible factors (HIFs), which are an evolutionarily conserved class of transcription factors and key mediators of the cellular response to hypoxia (Fig. 1).²⁶ There exist three HIF factors, which are transcriptional heterodimer complexes composed of a conditionally available α subunit (HIF-1 α , HIF-2 α , and HIF-3 α) and an always present β subunit, the aryl hydrocarbon receptor nuclear translocator (ARNT). All α subunits contain an oxygen-dependent degradation domain (ODD). Under normoxic conditions, α subunits are hydroxylated at proline residues in their ODD by enzymes called prolyl hydroxylase domain (PHD) proteins, leading to their recognition by the von Hippel-Lindau (VHL) E3 ubiquitin ligase. VHL attaches a chain of ubiquitin proteins to the HIF α subunits (ubiquitination), which leads to recognition and degradation by the proteasome.²⁷ Low oxygen levels lead to a graded decrease in the enzymatic activity of PHD proteins (half-maximum at 15–20 μ M O₂, or around 2% O₂), thereby stabilizing HIF protein complexes.²⁸ As a result, they accumulate and translocate to the nucleus, where they execute their transcriptional activities by binding to HIF-responsive elements (HREs), subsequently increasing the expression of a large set of HIF-responsive genes that ensure proper adaptation to the detected hypoxic conditions.^{26,29} The distinct HIF transcriptional complexes have both overlapping and unique gene targets, and also exhibit distinct functions *in vivo*.³⁰ HIF-1 α is associated with upregulation of genes needed for cell survival in low-oxygen environments, while HIF-2 α promotes the transcription of genes related to stem cell behavior, such as octamer-binding transcription factor 4 (OCT4), NANOG and c-MYC.³⁰ HIF-3 α is much less studied, though it also acts as a transcription factor and is upregulated in various pathological situations, as for instance in heart failure.³¹ In certain cell types and contexts HIF-1 α drives the initial response to acute hypoxia, while HIF-2 α takes over during chronic hypoxia due to the activity of hypoxia-associated factor,³² a ubiquitin ligase that binds and adds a ubiquitin protein chain to HIF-1 α , leading to its degradation. HIF-1 α affects the transcription of genes in many different cellular processes. By increasing the






Fig. 1 Importance of hypoxia in physiological and pathological processes. Schematic representation of the most important signalling pathways controlled by oxygen (middle), petals around indicating a few examples of essential physiological and pathophysiological processes that are significantly influenced by oxygen levels. ATF6, activating transcription factor 6; ARNT, aryl hydrocarbon receptor nuclear translocator; ER, endoplasmic reticulum; HIF1, hypoxia-inducible factor 1; HRE, hypoxia response element; IRE1, inositol-requiring enzyme 1; mTOR, mammalian target of rapamycin; PERK, protein kinase R (PKR)-like endoplasmic reticulum kinase; PHD, prolyl hydroxylase domain; UPR, unfolded protein response; VHL, von Hippel-Lindau.

transcription of glucose transporters such as glucose transporter 1 (GLUT1) and glycolytic enzymes such as hexokinase 1 (HK1), aldolase A (ALDOA) and pyruvate kinase (PKM), HIF-1 α is responsible for switching energy production in hypoxic cells from an oxygen-dependent oxidative phosphorylation to an oxygen-independent glycolysis, which in the context of cancer leads to an enhanced aggressiveness.³³ Additionally, by regulating the transcription of vascular endothelial growth factor (VEGF), HIF-1 α and HIF-2 α signalling also stimulates angiogenesis.³ Other physiological processes affected by HIF signalling include, for instance, immune suppression and cell migration.^{34–36}

Alternative oxygen sensing pathways

Other pathways that respond to low oxygen levels are the unfolded protein response (UPR) and the mammalian target of rapamycin (mTOR) pathway. The UPR pathway is a transcriptional induction pathway activated in cells undergoing endoplasmic reticulum (ER) stress (Fig. 1).³⁷

Under hypoxic conditions, unfolded and misfolded proteins accumulate in the ER, which can be explained by the oxidizing potential of oxygen that supports disulphide bond formation in post-translational folding.³⁸ In non-stressed cells, the UPR mediating stress-responsive proteins activating transcription factor 6 (ATF6), inositol-requiring enzyme 1 (IRE1) and protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK) are maintained in an inactive state through interaction with glucose regulated protein 78 (GRP78), also referred to as binding immunoglobulin protein (BiP).³⁹ Upon the accumulation of unfolded or misfolded proteins and ensuing ER stress, these stress-responsive proteins are released and trigger the UPR pathway to enhance the transcription of genes involved in cell survival^{40–42} and ER capacity.^{43,44} mTOR is a central nutrient sensor that regulates growth, metabolism, cell survival and autophagy.⁴⁵ mTOR signalling is sensitive to oxygen levels through various independent signalling pathways.²⁵ One energy-dependent pathway, for instance, involves sensing of reduced ATP



production by oxidative phosphorylation due to limited oxygen availability, which activates AMP-activated protein kinase (AMPK). AMPK in turn phosphorylates the tuberous sclerosis protein 1 (TSC1)–TSC2 complex,⁴⁶ which represses mTOR through acting as a GTPase-activating protein toward the mTOR-activating small GTPase Rheb.⁴⁷

Role of oxygen at the tissue level in healthy conditions

Tissue oxygenation is one of the most crucial processes in human physiology as it is closely related to (energy) metabolism and cellular survival, and it involves a multitude of intracellular signalling cascades, some being introduced above. From inhalation of air to oxygen diffusion across alveolar membranes, transport on haemoglobin in red blood cells and diffusion into tissues, oxygen availability is very tightly regulated *in vivo* at the entire body level. The oxygen concentration drops from 20.9% in the troposphere to approximately 12% in arterial blood, and decreases further to ~5% in venous blood due to oxygen consumption throughout the body.⁴⁸ Physiological oxygen concentrations vary greatly between and within tissues in the human body, and oxygen gradients in certain tissues often play important (patho)physiological roles (Fig. 1). Methods to determine oxygen concentrations in tissues *in vivo* vary considerably, and different approaches often yield somewhat distinct values for the same tissues.^{3,48} Nevertheless, bulk measurements have revealed that organs with a relatively high average oxygen concentration include ovaries (~11.5%) and the renal cortex (~9.5%), while tissues with lower average oxygen concentrations include muscle fibres (3.8%) and the brain (4–6%) (Fig. 2).^{3,48} Despite the comparatively low oxygen pressure in the brain, neurons are extremely sensitive to hypoxia, causing rapid and irreversible brain damage after oxygen deprivation.⁴⁹ Noteworthy, controlling oxygen tension is also a major challenge in the formation of brain organoids,⁵⁰ which as soon as they reach a certain size, are likely to present a hypoxic core.

In the liver, oxygen concentrations vary significantly (from ~4 to 13%) and are directly linked to so-called zonation. Three zones can be distinguished in a liver sinusoid between the central vein and the space where the blood flows coming from the portal vein and hepatic artery are mixed. The oxygen content decreases going from the latter region to the former, and each of the three zones is characterized by a different O₂ percentage which impacts both the cell metabolic capacities and their cytokine secretion profile.^{51–53} As such, liver zonation with these distinct oxygen levels should be incorporated for toxicity screening, liver disease models and metabolic studies. Noteworthy, normal early embryo development happens in a hypoxic environment, estimated to be at 1.5–2% O₂ in the uterus of rhesus monkeys.¹⁸ The low oxygen tension plays a crucial role in regulating stem cell fate and developmental morphogenesis.⁹ In line with this observation, growing embryos for *in vitro* fertilization (IVF)

at 5% O₂ instead of atmospheric conditions of 20% O₂ benefits their quality and has been reported to result in more live births per embryo transfer.^{54,55} Hypoxia also plays a dual role in wound healing. In the initial stages, it is beneficial and sets in motion a wide array of processes, including the upregulation of genes that enhance healing processes through HIF-1 α stabilization.⁵⁶ Prolonged hypoxia is however detrimental: it delays the entire wound healing process, and can even contribute to the generation of non-healing ulcers.¹¹


Importance of oxygen levels in disease

As alluded to before, the importance of hypoxia has been established in a wide range of pathologies (Fig. 1). In the case of cardiovascular diseases, tissues are often exposed to hypoxia and even anoxia after a stroke, and intermittent hypoxia is linked to high blood pressure and myocardial ischemia due to sleep apnoea.⁵⁷ Fibrotic diseases are also strongly associated to the pro-inflammatory, angiogenic, and fibrogenic effects of chronic hypoxia.^{58,59} Further examples are provided in the last section of this review (Table 3). Yet, the prime example of the importance of hypoxia in a pathological situation is in advanced solid tumours, which we discuss in more detail in the following paragraph.

In solid tumours, oxygen concentrations are usually very low, due to the limited penetration and diffusion of oxygen into these dense and relatively poorly vascularized tissues. Distances between vessels are typically greater than the average oxygen diffusion length of a few hundreds of microns.⁶⁰ On average, oxygen concentrations in tumour tissues range from 1 to 2%, but can be as low as 0.3% in the case of pancreatic tumours.³ Such a low oxygen concentration leads to both direct and indirect metabolic adaptations: *e.g.*, directly with lower ATP generation by oxidative phosphorylation and the inhibition of fatty acid desaturation, and indirectly by mediating hypoxia-induced changes in gene expression levels,⁶¹ causing a reduced pH and the release of angiogenic factors.⁶² Hypoxia is also associated with increased reactive oxygen species (ROS) levels,⁶³ enhanced probability for cancer metastases through increased inflammation and enhancing the epithelial-to-mesenchymal transition (EMT),⁶⁴ and therapy resistance,⁶⁵ notably due to the fact that cells switch metabolism profiles, which facilitates entry into a quiescent state. Hypoxia furthermore leads to immune evasion, thereby negatively affecting the efficacy of immunotherapies.⁶⁶ As tumours are heterogeneously oxygenated, regions in tumours that are relatively distant from the nearest functional blood vessel can become fully anoxic, meaning oxygen levels below 0.02%.⁶⁷ When this happens, cells undergo necrosis, leading to the formation of a necrotic core. Next to the degree of hypoxia, the temporal nature of exposure to hypoxic conditions is an important factor with a significant impact on tumour cell behaviour. Tumour cells can be exposed to chronic hypoxia, which occurs in cells located too far away from a blood vessel



A



B

Anoxia	Exposure to extremely low levels of oxygen (< 0.02%), which often leads to necrosis
Hypoxia	Exposure to low levels of oxygen that activate adaptive responses of the cells or tissues. Depending on the tissue, this usually occurs below 3-5% oxygen
Physioxia	Exposure to normal levels of oxygen as happens inside the body, ranging from ~4-12% depending on the tissue
Normoxia	Exposure to atmospheric levels of oxygen (~20%). This is often hyperoxic for tissues in <i>in vitro</i> conditions
Hyperoxia	Exposure of cells and tissues to oxygen levels that are supraphysiological

Fig. 2 Examples of oxygen levels in several tissues in the human body. (A) Various organs are depicted with their respective tissue oxygen levels, emphasizing that oxygen levels are widely different in tissues, which is usually not taken into account in *in vitro* cell or tissue models. (B) Glossary of terms to describe exposure to various oxygen levels.

and in an environment with a high cell density. Alternatively, acute hypoxia is a sudden (irreversible) establishment of hypoxia, for example due to sudden closure of a blood vessel induced by the pressure exerted by the increased tumour mass.⁶⁸ Finally, cyclic or intermittent hypoxia is a state where cycles of hypoxia followed by reoxygenation occur due to transient shutdowns of the poor-quality tumour vasculature.^{68,69}

Controlling the oxygen tension in a microfluidic device

Different approaches have been developed to accurately control the oxygen tension in microfluidic devices in combination with both 2D and 3D cell culture models (Fig. 3), with the underlying aim to precisely model the gas



concentrations found in physiological or pathological conditions in specific tissues or organs. Concrete aims are usually to generate hypoxic conditions, either in a chronic or in a cyclic manner, or to create an oxygen gradient across a cell culture. These approaches can broadly be classified in two main categories: on one hand, engineering approaches implemented at the device level during its fabrication, *e.g.*, through proper choice of materials employed to build the microfluidic device (Fig. 3A and B), and, on the other hand, chemical approaches that involve the active perfusion of fluids oxygenated at a precise level, or fluids supplemented with oxygen-producing or oxygen-scavenging chemicals (Fig. 3C). Noteworthy, a few reports combine these two approaches (Fig. 3D). Finally, open-well configurations have also been proposed either with membranes separating gas channels from a cell culture area in an open well (Fig. 3E, top) or in devices assembled in blocks of oxygen-permeable or impermeable materials (Fig. 3E, bottom). Since other reviews have extensively described the microfabrication process as well as the set up and validation of oxygen control in such devices,^{70–72} here, only a brief overview of all approaches is provided.

Engineering approaches to control the oxygen tension in a microfluidic device

Microfluidic devices meant for cell culture experiments and to create organ models are mostly fabricated from the elastomeric material PDMS, or polydimethylsiloxane, which is gas permeable, its permeability to oxygen being $4.1 \times 10^{-5} \text{ cm}^2 \text{ s}^{-1}$.⁷³ This property, which was initially identified as an advantage to ensure cells in a device would be supplied with adequate amounts of oxygen and carbon dioxide,²² can actually turn out into a major limitation when wanting to tune the oxygen tension and/or create physioxia or hypoxia culture conditions to emulate the *in vivo* situation. Therefore, a first obvious alternative is to not use PDMS, but a gas-impermeable material such as glass,⁷⁴ SU-8^{75,76} or a thermoplastic like polystyrene (PS)^{77,78} or cyclic olefin copolymer (COC) (Fig. 3B),⁷⁸ or even a combination of a thermoplastic with another material to increase the barrier function of the device.⁷⁸ Alternatively, still with the aim of blocking free oxygen diffusion into the cell culture area, a gas-impermeable material can be embedded in a PDMS-based device, which has notably been achieved using polymethylmethacrylate (PMMA)^{79,80} or polycarbonate (PC) substrates (Fig. 3A).^{81,82} The main advantage of this engineering approach is that the oxygen tension in the device and the cell microenvironment is set by the cells themselves, which are actively consuming oxygen. This scenario is in theory analogous to the *in vivo* situation in which the metabolic activity of cells, together with the delivery of oxygen through the circulation, are decisive for the local oxygen tension in a tissue and the possible presence of gradients thereof. Still, for this ideal physiological scenario to be achieved, culture parameters must be adequately scaled,

like the cell-liquid ratio for instance, to ensure cell metabolism and oxygen delivery are matching the *in vivo* situation.

Chemical approaches to control the oxygen tension in a microfluidic device

The second approach is of a chemical nature and relies on active perfusion of fluids (liquids or gases) conditioned at a given oxygen concentration or supplemented with chemicals to scavenge or generate oxygen. This chemical approach provides more flexibility in the experimental design to possibly alter dynamically and on-demand the oxygen concentration in the device and the tissue microenvironment, *e.g.*, to create intermittent or chronic hypoxia, which is important to model an ischemic shock, for instance.^{83–85}

In a first example, medium containing an appropriate oxygen concentration was directly perfused on a multi-layer cellular model of the liver sinusoid, in the view of modelling the oxygen zonation found in this tissue.⁸⁶ The flow rate and the channel height were both adjusted to not introduce any bias due to the permeation of oxygen through the PDMS; a shallow oxygen gradient was found both experimentally and through modelling, along the channel, but only in its top part, and with no impact on the cellular model. Most of the time the pre-conditioned fluids are not perfused directly onto the cell culture, but in additional channels or structures in the device, leveraging once more the high gas permeability of the PDMS material. These additional channels are typically located above^{83,84,87} or below⁸⁸ the cell culture area, with gas permeation occurring through a thin PDMS membrane placed between the culture chamber and the control channels. When using one broad control channel covering the entire cell culture area, the latter is homogeneously exposed to the same oxygen tension, which can however be changed over time. Gradients of oxygen have also been successfully created across a cell culture, by using two control channels placed on the two sides of the culture area and perfused with air and nitrogen.^{88,89} By changing the distance between the two control channels and the composition of the gas perfused therein, the gradient characteristics such as the range and shape/slope can easily be adjusted.⁸⁸ Yet another approach to control oxygen levels made use of silicone hydrogel synthetic vessels for the controlled delivery of oxygen to a 3D cancer cell culture.⁹⁰

Instead of employing pre-conditioned fluids, solutions can be supplemented with chemicals to actively and *in situ* alter the dissolved oxygen concentration, through its consumption by oxygen-scavenging species such as sodium sulphite^{80,85,91,92} and pyrogallol/NaOH^{93,94} or its production by oxygen-producing species such as a combination of hydrogen peroxide and NaCl.⁹³ In a first example, Bulutoglu *et al.* directly perfused a solution of sodium sulphite and cobalt sulphate onto cellular models;⁹² specifically, thanks to a gradient generator located upstream to an array of culture






Fig. 3 Approaches to control oxygen in microfluidic devices. An overview and schematic representation of various approaches to control the oxygen tension in microfluidic devices is given, showing the cross-sectional view of the device in which a 3D cell model is created in a hydrogel matrix. (A) Devices with embedded oxygen-impermeable substrates. (B) Devices made entirely from oxygen-impermeable substrates. (C) Devices in which oxygen control is set using oxygen-scavenging or oxygen-generating molecules or controlled gas injection. (D) Hybrid devices combining multiple approaches simultaneously to control oxygen. (E) Open-well devices with a gas-permeable membrane between gas channels and a cell culture area in an open well (top) or hybrid open-well devices assembled in blocks combining layers of oxygen-permeable and -impermeable material, and with an open reservoir for addition of medium (bottom). COC, cyclic olefin copolymer; H_2O_2 , hydrogen peroxide; Na_2SO_3 , sodium sulphite; PC, polycarbonate; PMMA, polymethyl methacrylate; PS, polystyrene.



chambers, they exposed hepatocyte monolayers to medium oxygenated to specific levels, as found in the different zones in the liver, and containing various concentrations of free fatty acids, to create a non-alcoholic fatty liver disease (NAFLD) model. To prevent direct contact between cells and oxygen-scavenging and oxygen-producing chemicals, these are like the pre-conditioned fluids described above also most often perfused in channels adjacent to the cell culture area⁹³ or located below it.⁹¹ A thin PDMS membrane separates the culture chambers from these control fluidic lines, through which gases can diffuse easily, which is analogous to having oxygen diffusing across alveolar membranes in the lung.

To create gradients of oxygen across a cell culture area, the latter can be flanked on one side only by one channel, perfused with oxygen-scavenging chemicals, acting as a sink,^{85,94} or by two channels perfused respectively with oxygen-scavenging and oxygen-generating chemicals,⁹³ acting, respectively, as a sink and a source.

Hybrid engineering/chemical approaches to control the oxygen tension in a microfluidic device

Finally, a handful of reports have combined engineering and chemical approaches to add a dynamic component to the system or to ensure the system remains at a given oxygen concentration. In all cases, a gas-impermeable substrate was introduced in a PDMS fluidic layer, while actively perfusing in dedicated side channels either sodium sulphite to scavenge oxygen on one side of a cell culture chamber⁸⁰ to generate an oxygen gradient across it, or gas mixtures on both sides to create hypoxic, normoxic conditions, or an oxygen gradient, and to be able to switch between these different scenarios on-demand.^{81,82,95–97}

Readout – sensors

As a first readout, oxygen sensors can be integrated in the microfluidic device, with the primary aim to experimentally characterize the devices when the oxygen tension is actively controlled or to correlate the oxygen tension with other biological, physical, or cellular parameters. While some sensors have been developed to evaluate the oxygen consumption and/or metabolism of (individual) cells, tissues, or embryos,^{98,99} they can equally be employed to monitor the oxygen tension in miniaturized devices. Two approaches dominate for on-chip oxygen sensing, using either electrochemical¹⁰⁰ or optical detection,¹⁰¹ which are both discussed in more detail in the following. It is worth noticing that other approaches are also widely employed to evaluate the impact of hypoxia on cells and tissues and to examine their biological response. These include the detection of metabolic markers with various microscopy techniques or collection of cells and investigation of protein and/or gene expression levels. Since these techniques by themselves belong to the standard biochemical toolbox of molecular and microscopy analysis and are not specific for the study of

hypoxia, we will not discuss them in depth in the text, but they are summarized in Table 1.

Electrochemical sensing

Electrochemical sensors mostly consist of miniaturized electrodes, which are fabricated as part of the substrates of the device. They come as miniaturized Clark electrodes,¹⁰² ultra-microelectrodes (UMEs) – and mostly arrays thereof,^{98,103,104} with different geometries and are based on various metal and oxide materials. Yet, they all rely on the same sensing principle: the reduction of the oxygen in solution, which generates a current directly proportional to the dissolved oxygen concentration. As summarized in Table 1, the main advantages of these electrochemical sensors are: (a) their sensitivity; (b) ease of miniaturization and integration in a microfluidic device; (c) suitability to record at different surface locations in the device and image oxygen gradients simply by adapting the sensor geometry; and (d) the possibility to correlate oxygen concentration with other (metabolic) parameters, measured using the same electrode or another sensor. At the same time, limitations associated with electrochemical sensing are: (a) the possible toxicity of the electrode materials; (b) the impossibility to access three-dimensional information, which is particularly important when working with 3D cellular constructs; (c) the possible interference of other species in solution also reduced at the same potential; (d) electrode biofouling through uncontrolled adsorption of proteins such as albumin on the electrode surface, a widely encountered issue that leads to a progressive reduction in the active sensing area, and; (e) more importantly, the active consumption of oxygen through the measurements which may deplete oxygen in the direct vicinity of the cells, and give rise locally to oxygen levels that are significantly lower than initially targeted. This can easily become critical when working with microliter to sub-microliter volumes and small oxygen amounts, as is the case in microfluidic devices.

Readers interested in such microsensors for on-chip monitoring of oxygen as well as other parameters of the cell metabolism, are referred to a recent review by Kieninger *et al.*¹⁰⁰ Of particular interest is recent work in which the same RuOx-based sensor was employed in a Transwell system to dually monitor and thereby correlate two essential parameters in the cellular microenvironment, namely the oxygen tension and acidification rate, to characterize the metabolic activity of cardiomyocytes supplied with either glucose- or galactose-supplemented medium.¹⁰⁵ To address one major limitation of electrochemical sensing, which is the consumption of oxygen by the measurements, van Rossem *et al.* proposed an innovative approach combining an UME array and millisecond time scale recordings, reducing significantly the magnitude the oxygen consumption while still supporting real-time and continuous measurements.¹⁰⁴



Table 1 Techniques and/or readout approaches for oxygen levels in microfluidic devices

Level	Technique/readout	Purpose/application	Time/location	Advantages	Limitations/risks
Device level	Electrochemical sensing	Spatio-temporal mapping of oxygen concentration	Real-time	High sensitivity	Integration of electrodes
		Correlation between O ₂ concentration and biological response	<i>In situ</i>	Fast response time	Toxicity of the sensor materials
				Ease of miniaturization	Planar (2D) information
	Optical sensing/bioluminescence			Multi-parametric sensors	Sensor biofouling
					Interference with other species in solution
					Active consumption of O ₂
			Real-time	No O ₂ consumption	Toxicity of the probes
			<i>In situ</i>	High sensitivity	Generation of ROS
				Fast response time	Planar (2D) information if planar sensor and not embedded in a 3D hydrogel matrix
				Two measurement schemes (time-resolved and intensity)	Need for bulky optical instrumentation
				Microscopes ubiquitous in life sciences labs	
Cellular & tissue levels	Fluorescence	O ₂ level and gradients thereof	Real-time	Microscopes ubiquitous in laboratories	Loss of fluorescence over time/bleaching
			<i>In situ</i>		
	Fluorescence microscopy	Hypoxia imaging (hypoxia-sensitive fluorescent probes)	Live cell imaging	Well-established protocols	Altered behaviour of fluorescently labelled species (molecules, cells)
			<i>In situ</i>	Non-invasive	
	(Fluorescence) microscopy	Cell metabolism (fluorescent glucose analogue 2-NBDG)	Live cell imaging	Continuous measurements	Cell transfection/engineering in some cases – for specific marker of interest (signalling pathways) or cell tracking using fluorescence microscopy
		Cell migration, proliferation, quiescence	<i>In situ</i>	Possibly real-time information	
		Apoptosis, cell viability (drug response)		Little to no (photo) toxicity	
		Tissue size and variations thereof depending on the O ₂ tension (swelling)		3D information	
		ROS production (ROS-sensitive fluorescent probes)		Measurements possibly inside cell culture incubators	
		Signaling pathway activation (<i>e.g.</i> , HIF, UPR)			



Table 1 (continued)

Level	Technique/readout	Purpose/application	Time/location	Advantages	Limitations/risks
	Immunoassays (ELISA, Luminex)	Inflammation	Off-line	Well-established protocols	Dependent on antibody availability
		Intercellular signalling		Suitable for continuous measurements and on-line analysis	Labour intensive
		Metabolism			Expensive to multiplex
		Tissue function			
	Immunostaining and fluorescence microscopy	OoC characterization	Endpoint	Well-established protocols	No continuous monitoring
		Protein expression (levels)	<i>In situ</i> or off-line	Microscopes ubiquitous in laboratories	Sample sacrifice
		Signaling pathway activation			Difficult to implement with 3D cellular models and on-chip when using multi-material devices
		Triggering of biological processes			Dependent on antibody availability
	RT-qPCR	Gene expression levels for specific processes/pathways	Endpoint	Well-established protocols	Limited number of samples: pooling of multiple devices
			Off-line	Easy design of primers Suitable for all transcripts, including miRNA	Lack of spatial information
	RNA Seq	Gene expression profiles	Endpoint	Downscalable to the single cell level	Limited number of samples: pooling of multiple devices
			Off-line	Comprehensive gene expression analysis	Lack of spatial information unless implemented at the single cell level in combination with regiospecific cell extraction
					High cost per sample
	LC-MS/MS	Protein expression profiles (proteomics)	Endpoint	Comprehensive or targeted analysis	Limited number of samples: pooling of multiple devices
			Off-line	Sub-proteomics analysis (PTM profiling)	Lack of spatial information High cost per sample
		Secretomics	Real-time (possibly)	Suitable for continuous measurements and on-line analysis	Need for dedicated sample preparation if online analysis
		Metabolism	<i>In situ</i> or off-line		High cost per sample

ELISA, enzyme-linked immunosorbent assay; LC-MS, liquid chromatography mass spectrometry; OoC, organ-on-a-chip; PTM, post-translational modifications; ROS, reactive oxygen species; RT-qPCR, reverse transcription quantitative polymerase chain reaction.

Optical sensing

Optical sensors employ oxygen-sensitive luminescent probes, in the form of coordination metal complexes based on Pt, Pd or Ru. Their luminescence is quenched in the presence of oxygen, and the higher the measured luminescence intensity,

the lower the oxygen tension.¹⁰⁶ Alternatively, time-resolved measurements are employed, which consider the lifetime of the luminescence probe.^{101,106} This latter detection scheme is less sensitive to background noise due to the autofluorescence of other species in the sample, and photobleaching.^{101,106} For oxygen sensing, these luminescent



probes can be introduced in different manners in a microfluidic device. First, they can be added to the culture medium, either freely in solution provided they are water-soluble^{86,94,107,108} or after embedding in microbeads,¹⁰⁹ which limits direct interactions of the probe with the living biological sample and reduces toxicity concerns. Alternatively, they are encapsulated in a solid material and embedded in a continuous or patterned polymer thin film¹¹⁰ placed at the bottom or top of the device, or in prefabricated trenches in the PDMS roof,¹¹¹ approaches which equally limit interactions of the probes with the biological sample.

Fluorescence microscopes are ubiquitous in biological labs, which makes this optical sensing approach very attractive compared to electrochemical measurements. Furthermore, it does not alter the cell microenvironment by consuming oxygen. However, optical measurements mostly require bulky instrumentation, which makes them less suitable for full integration and miniaturization. Furthermore, fluorescent chemical probes can be toxic to cells directly exposed to them¹⁰⁷ or, indirectly, through the photo-induced production of radical species.¹¹² Finally, thin-film optical sensors, as their electrochemical counterparts, only reveal 2D information on the oxygen concentration in the vicinity of the sensors, while 3D cellular models, which are more relevant, exhibit an inhomogeneous oxygen distribution in all three dimensions, and often have little to no oxygen in their core. To address this last limitation, Ru-based oxygen-sensitive probes have been covalently attached to a collagen hydrogel, which was subsequently employed as a matrix to create a 3D cellular construct in a microfluidic device, possibly allowing 3D mapping of the oxygen distribution in the resulting tissue.¹¹³

Biological applications of hypoxia in microfluidic devices

Although there have been major efforts in developing methods to control and measure the oxygen tension in microfluidic devices, as discussed in the previous sections, usually these devices have only been validated by confirming well-known biological or pathological processes affected by oxygen levels, as an understandable first proof-of-concept step. Nevertheless, several studies have already provided interesting insights, *e.g.*, with respect to the relation between oxygen levels and cell migration,^{82,87,93–97,114–116} ROS production,^{74,117–119} activity of HIFs^{88,120,121} and metabolic changes.^{77,79,122,123} Other work has focused on intermittent *vs.* chronic hypoxia^{81,83,87,124} or investigated targeting of hypoxia by hypoxia-responsive drugs.^{93,125,126} An overview of these studies is presented in Table 2 and is discussed in this section.

Cell migration along oxygen gradients

As a first application, the migratory behaviour of cells has been investigated along oxygen gradients in 2D and 3D cellular models. In particular, the motility of PANC-1

pancreatic cancer cells through a collagen gel was found to increase under hypoxic conditions, with marked directionality towards higher oxygen tensions.⁸⁷ MDA-MB 231 breast cancer cells seeded as a 3D model in collagen or fibrin hydrogels showed a similar behaviour, with enhanced motility and directionality towards higher oxygen concentrations, as imaged using confocal microscopy.^{82,96} Interestingly, aggressive MDA-MB-231 breast cancer cells and cancer stem cells, both cultured as a monolayer, were found to migrate towards hypoxic areas,⁸⁰ showing an opposite migratory behaviour. The authors hypothesized that this different behaviour could be explained by the fact that their model only included an oxygen gradient, unlike other devices where other gradients, *e.g.*, glucose gradients, co-occurred with the oxygen gradient. Still using the same aggressive breast cancer cell line, cultured in 3D in collagen, molecular analysis was performed, confirming the activation of the HIF-1 signalling pathway under hypoxic conditions.⁸²

In a device fabricated from SU-8, hypoxia-driven cell migration was observed with the formation of pseudopalisades,¹²⁷ which are tumour regions with high cell density where tumour cells are hypoxic and overexpress HIF-1 α . Pseudopalisades are typical structures of glioblastoma and are linked to an enhanced migration due to an epithelial–mesenchymal transition induced by HIF-1 activity.¹¹⁵ In another device flanked by an oxygen-depleting channel on one side and an oxygen-generating channel on the opposite side, gradients were reported to impact A549 cell migration, which was linked to an increased secretion of transforming growth factor β (TGF- β) under hypoxic conditions.⁹³ The interactions between fibroblasts and cancer cells,⁹⁴ as well as the response of cancer cells to various anti-cancer drugs, were also affected by this oxygen gradient.⁹³

Healthy endothelial cells, on the contrary, migrated towards lower oxygen concentrations when grown as a 2D model, corroborating the importance that oxygen gradients play in guiding and regulating angiogenesis.¹¹⁶ Funamoto *et al.* evaluated the impact of hypoxic conditions on the integrity of an endothelium lining; barrier function was significantly impacted by the hypoxic conditions and adhesion molecules were internalized by the cells, as revealed by on-chip immunostaining.⁹⁵ Endothelial cell migration was also imaged in the same platform, under hypoxic *vs.* normoxic exposure,⁹⁷ using particle imaging velocimetry (PIV). As was the case for cancer cells, migration was enhanced under hypoxic conditions, which was associated with a decrease in VE-cadherin expression, and stabilization and nuclear translocation of HIF-1 α , which confirmed the active sensing and cellular response activation to the presence of hypoxia.

ROS production and ER stress in response to changes in oxygen tension

Cells grown under hypoxic conditions are known to produce increased levels of ROS, although the exact mechanisms for



Table 2 Overview of biological applications of microfluidic devices with oxygen control

Biological process	Method of oxygen control	Cell type	Techniques	Readouts	Ref.
Cell migration	Hybrid: oxygen impermeable material and chemical oxygen control in gas channel (Fig. 3D)	MDA-MB-231 ^a	Real-time microscopy	Cell migration trajectory	82
	Chemical control of oxygen in gas channel (Fig. 3C)	PANC-1 ^b	Phase contrast microscopy	Cell migration along oxygen gradient in a collagen matrix	87
	Chemical control of oxygen in gas channel (Fig. 3C)	MDA-MB-231 ^a	Real-time microscopy	Cell net displacement, trajectory, directionality. Cell viability	96
	Chemical control of oxygen in leaching channel with oxygen scavenging-chemicals (Fig. 3C)	HUVEC ^c	Real-time microscopy	Speed of collective cell migration	116
ROS production and ER stress	Open-well device with gas-permeable membrane and chemical oxygen control in gas channels (Fig. 3E top)	MDCK ^d	Real-time microscopy	Intracellular fluorescence of ROS-sensitive dyes	119
	Open-well device with gas-permeable membrane and chemical control of oxygen in gas channels (Fig. 3E top)	CHO ^e cells stably expressing 6 U-HIF-binding repeats (HBR) as a reporter of HIF- α stabilization A549 ^f cells expressing a redox-sensitive fluorescent biosensor in the mitochondria	Fluorescence microscopy	Changes in fluorescence intensity of the HBR reporter and redox probe in the mitochondrial membrane	117
	Hybrid: chemical control of oxygen in gas channel and gas-impermeable materials (Fig. 3D)	MCF-12A ^g and MDA-MB-468 ^h	Fluorescence microscopy	Fluorescent ER stress indicator thioflavin T	118
	Chemical control of oxygen in gas channel (Fig. 3C)	hCMEC/D3 ⁱ	Fluorescence microscopy	Immunofluorescence using anti-HIF-1 α and anti-HIF-2 α antibodies	88
HIF α stabilization and hypoxia-triggered metabolic changes	Hybrid: chemical control of oxygen in gas channels and layers of oxygen-impermeable materials stacked as a block (Fig. 3E bottom)	MDA-MB-231 ^a cell line transfected with a 5 $\times$ hypoxia response element (5HRE)/eGFP gene construct	Fluorescence microscopy	Expression of eGFP under hypoxia	120
	Open-well device with gas permeable membrane and chemical control of oxygen in gas channels (Fig. 3E top)	HLMVEC ^j and MSCs ^k	Fluorescence microscopy	Immunofluorescence with anti-HIF-1 α antibody	122
			Western blot	Analysis of LDHA expression	
			RT-qPCR	Quantification of gene expression	
	Oxygen-impermeable material embedded in PDMS (Fig. 3A)	U-251-MG ^l	Fluorescence microscopy	Imaging of the fluorescent hypoxia sensor Image-iT, the fluorescent glucose analogue 2-NBDG uptake and the pH-sensitive TR/fluoro-labelled dextran	79
	Oxygen-impermeable materials in the form of a cap and pillars (Fig. 3A)	MCF-7 ^m	Fluorescence microscopy	Immunofluorescence of GLUT-1	132
			RT-qPCR	Gene expression analysis after laser microdissection of different regions of the device	



Table 2 (continued)

Biological process	Method of oxygen control	Cell type	Techniques	Readouts	Ref.
Intermittent hypoxia and co-cultures with hypoxic cells	Hybrid: oxygen-impermeable material embedded in PDMS and chemical oxygen control in gas channels (Fig. 3D)	MDA-MB-231 ^a	Real-time microscopy	Cell migration speed. Cell distribution and proliferation under different oxygen conditions	81
	Chemical control of oxygen in gas channel (Fig. 3C)	Tumour spheroids from MCF-7 cells ^m	Brightfield, fluorescence microscopy, and two-photon microscopy	Monitoring of global spheroid size Volumetric changes of single cells	83
	Chemical control of oxygen in leaching channel with oxygen scavengers (Fig. 3C)	ECFC-ECs ⁿ made constitutively fluorescent and NHLF ^o	Real-time microscopy	Angiogenesis tracking of fluorescent endothelial cells	85
	Chemical control of oxygen in gas channel (Fig. 3C)	C57BL/6 mice-derived pancreatic islets	Off-chip insulin ELISA Fluorescence microscopy	Insulin production Rhodamine 123 fluorescence to observe changes in mitochondrial membrane potential	124
Barriers in microfluidic devices	Chemical control of oxygen in gas channel (Fig. 3C)	CaCo-2 ^p and primary HC2978 colon organoids from a patient	Fluorescence microscopy	Immunofluorescence of hypoxia markers	140
		Obligate anaerobic bacteria: <i>F. prausnitzii</i> , <i>Eubacterium rectale</i> , and <i>B. thetaiotaomicron</i> , with different degrees of oxygen sensitivity	RT-qPCR LC-MS/MS	Quantification of gene expression Analysis of metabolites produced by bacteria	
	Oxygen-impermeable materials (Fig. 3B)	CaCo-2 ^p Facultative anaerobic bacteria <i>Escherichia coli</i> and obligate anaerobic <i>Bifidobacterium adolescentis</i>	Fluorescence microscopy	Imaging of intracellular fluorescent hypoxia sensors, actin cytoskeleton and tight junctions, or GFP expression in bacteria under hypoxic conditions	141
Hypoxia-targeted therapies	Chemical control of oxygen in leaching channel with oxygen scavengers (Fig. 3C)	A549 ^f	Brightfield and fluorescence microscopy	Live/dead cell ratios using calcein AM and ethidium homodimer-1 after drug treatment	93, 126
	Chemical control of oxygen in leaching channel with oxygen scavengers (Fig. 3C)	A549 ^f and HeLa ^q cells	Fluorescence microscopy	Cell viability staining using acridine orange and propidium iodide (AO/PI) to assess oxygen-drug interactions	93, 126
	Oxygen-impermeable materials (Fig. 3B)	SKOV3 ^r	Fluorescence microscopy	T-cell toxicity using calcein AM/propidium iodide (live dead assay)	125
		T-cells isolated from PBMCs, ^s CAR-T ^t cells containing scFv 4D5 (anti-HER2)		Immunofluorescence of GLUT-1 and PD-L1 in tumour cells, and CD45 for T-cell infiltration	

^a Human breast adenocarcinoma. ^b Human pancreatic ductal cell carcinoma. ^c Human umbilical vein endothelial cells. ^d Madin-Darby canine kidney cells. ^e Chinese hamster ovary cells. ^f Human alveolar basal epithelial adenocarcinoma cells. ^g Non-tumorigenic mammary epithelial cells. ^h Human breast adenocarcinoma. ⁱ Human brain microvascular endothelial cells. ^j Human cerebral microvasculature endothelial cells. ^k Human bone marrow derived MSCs. ^l Human glioblastoma astrocytoma cells. ^m Human breast invasive ductal carcinoma. ⁿ Endothelial colony forming cell-derived endothelial cells. ^o Normal human lung fibroblasts. ^p Human colorectal adenocarcinoma cells. ^q Human cervical carcinoma cells. ^r Human epithelial ovarian cancer cells. ^s Peripheral blood mononuclear cells. ^t Chimeric antigen receptor T-cells.

this remain unknown.^{128–130} Using microfluidic devices with a hypoxic microenvironment, ROS-related features have been investigated and correlated to the presence or absence of

hypoxia in the device. For instance, Lo *et al.*¹¹⁹ used an open-well device equipped with an array of underlying channels perfused with gas at different oxygen concentrations (similar



to Fig. 3E, top). A thin PDMS membrane separated the two structures, allowing the delivery of an oxygen gradient to Madin–Darby canine kidney (MDCK) cells seeded in the well. MDCK cells presented increased ROS levels under both hypoxic and hyperoxic conditions, which could be alleviated by an overnight incubation with vitamin C. ROS production by Chinese hamster ovary (CHO) cells was also quantified in a similar configuration, in an open-well chip with gas channels underneath.¹¹⁷ CHO cells were modified to express a mitochondrially-localized redox probe, whose fluorescence correlates with oxidation of the glutathione pool in the mitochondrial matrix. A decreased fluorescence was observed in response to the production of ROS under hypoxia, indicating a reduction in oxidative stress. This result was counterintuitive since ROS-induced oxidative stress would be expected to increase the oxidation of the (mitochondrial) glutathione pool and is indicative of subcellular differences in the (adaptive) response to ROS. Finally, using a hybrid device (similar to Fig. 3D) with chemical control of oxygen using a gas channel and a glass coating on the inner channel walls, ER stress was reported to increase along the oxygen gradient towards the lower oxygen areas, which was previously found to correlate with UPR activation,¹³¹ though this was not further investigated in that study.¹¹⁸

Activity of HIFs and hypoxia-triggered metabolic changes

As explained before, HIF-1 and HIF-2 complexes play major roles in the activation of cellular pathways in response to hypoxia following stabilization of the complex subunits HIF-1 α and HIF-2 α . Studies with microfluidic devices have shed new light on the role of these transcription factor complexes in hypoxia. For instance, PANC-1 cells grown in 2D were exposed to oxygen gradients created by perfusing oxygen and nitrogen compressed gases through two microchannels flanking the cell culture area (as depicted in Fig. 3C), and presented significant activation of HIF-1 α below 2.5% oxygen, while remarkably, HIF-2 α was activated along the entire gradient, even in the areas at normoxic conditions.⁸⁸ This finding led to the conclusion that the stabilization of HIF-2 α in normoxic cells is somehow mediated by the proximity of hypoxic cells. The underlying mechanism is not yet known but the authors hypothesized that it could include paracrine signals such as the secretion of exosomes, metabolites, or growth factors. Differences in cellular responses along an oxygen gradient were analysed using an open-well device assembled as a block with layers of silicone and acrylic in combination with oxygen control in gas channels (as depicted in Fig. 3E bottom).¹²⁰ MDA-MB-231 breast cancer cells which were stably transfected with a reporter that expressed enhanced green fluorescent protein (eGFP) controlled by hypoxia-response elements (5HRE/eGFP),¹²¹ which would thus be triggered by HIF1 or HIF2 activation, were cultured in a gel on the bottom of the well. As expected, the eGFP expression directly correlated with the oxygen tension. Specifically, the device was stratified in four areas based on the oxygen

tension, and in areas of the device where the oxygen tension was below 27 mmHg O₂ (~3.5% O₂) a higher oxidative stress was found that was associated with a greater hypoxic response, which was not the case in devices not exposed to an oxygen gradient, where the eGFP intensity did not change significantly.¹²⁰ Rexius-Hall *et al.* investigated the cellular response of human lung microvascular endothelial cells to oxygen tension in real-time using an open-well configuration equipped with two meandering gas channels below (device depicted in Fig. 3E top).¹²² This configuration allowed the creation simultaneously of both normoxic and hypoxic conditions having a small area in between with a steep oxygen gradient (0–21% O₂). Translocation of HIF-1 α to the nucleus was observed in these cells under hypoxic conditions, as well as upregulation of lactate dehydrogenase A (LDHA) expression, a downstream target of HIF-1. Upregulation of LDHA as well as other downstream target genes associated with metabolic switching towards glycolysis was also observed in human mesenchymal stem cells (MSCs), in the same device.

Several studies have focused on investigating the physiological effects of hypoxia on different cell markers and pathways related to cancer development, metastasis, and therapy resistance. One common response that tumour cells exhibit in a hypoxic microenvironment is the HIF-1-mediated increased reliance on glycolysis over oxidative phosphorylation.³³ For instance, Ayuso *et al.* demonstrated that natural oxygen gradients, as found in tumour tissues, could successfully be emulated in a PS-based oxygen-impermeable device, together with an associated biochemical gradient of glucose (device as depicted in Fig. 3B).⁷⁷ In recent work, we showed metabolic switching of U-251 glioblastoma cells in a microfluidic device with controlled hypoxia (device as depicted in Fig. 3A).⁷⁹ The gradient in oxygen towards the middle of the tumour cell-containing a 3D collagen gel, was associated with a decrease in pH, as well as an increase in the uptake by the cells of a glucose analogue. These observations indicate that the cells increase their reliance on glycolysis for an oxygen independent energy production, which is likely a consequence of enhanced HIF-1 transcriptional activities; yet this was not verified. The reproduction of these acidic conditions in a 3D model is essential since it is also associated with drug resistance. Finally, another study that used a circular cell culture area with a monolayer focussed on analysing the expression of genes involved in proliferation, apoptosis, glycolysis, and migration in MCF-7 breast cancer cells isolated from specific normoxic or hypoxic regions of the device.¹³² Downregulation of one proliferation gene (*MKI67*) as well as upregulation of genes involved in apoptosis, glycolysis and migration occurred in the most hypoxic region of the device, in comparison to the normoxic region.

Effects of intermittent hypoxia and co-cultures with hypoxic cells

Intermittent hypoxia has been found to influence cell migration, metabolic adaptation, and angiogenesis.^{68,69}



Leveraging the capability of microfluidic devices to provide spatiotemporal control on the oxygen tension, the response of tumour cells to this condition was examined.⁸¹ That study revealed an increased cell motility upon intermittent hypoxia, with an optimum motility in the region of the device with 5% oxygen. As discussed in a previous section, tumour cells and endothelial cells grown in 3D preferentially migrated towards slightly hypoxic regions (~5% oxygen). This was tested in a device with a hybrid method of oxygen control (as depicted in Fig. 3D) that used a PC embedded film and 8 h cycles of oxygen flow at different concentrations. An intermittent oxygen gradient was created towards the centre of the device by perfusing the oxygen at different concentrations through side channels next to the medium channels. The migratory behaviour was linked to the presence of metabolic or chemical gradients caused by the exposure to intermittent hypoxia. Interestingly, after cells were exposed to 8 h cycles of hypoxia, changes in migration speed occurred after approximately 4 h, even though the oxygen gradient in the device stabilized after 15 min. This observation could be explained by the time the α -subunits of HIF transcriptional complexes require after stabilization to translocate to the nucleus and upregulate the transcription of migration-related genes. Intermittent hypoxia was also applied in a device incorporating spheroids in collagen scaffolds, using a device with chemical oxygen control in side channels (as in Fig. 3C).⁸³ Surprisingly, spheroids displayed a dynamic swelling-and-shrinking behaviour following this cyclic hypoxia condition, which had a clear impact on drug delivery. This oxygen-dependent swelling seemed not to be caused by changes in cell-cell interactions but rather by cytoplasmic swelling of individual cells.⁸³

Both chronic and intermittent hypoxia also impact angiogenesis, which was studied using a co-culture of fibroblasts and endothelial cells in a fibrin hydrogel, leading to the formation of a 3D vascular network.⁸⁵ After formation of this network, fibroblasts alone in fibrin hydrogel were introduced in outer culture chambers to drive the expansion of the vasculature towards these chambers. To control the oxygen across the devices, two other channels were perfused with oxygen-scavenging chemicals and/or normal medium, continuously, or intermittently, allowing the formation of uniform hypoxic conditions, an oxygen gradient, or intermittent hypoxia. Both during chronic and intermittent hypoxia, angiogenesis was directed towards the side of the chamber with the lowest oxygen concentrations. This effect was also stronger during intermittent hypoxia than during chronic hypoxia, which is in good agreement with the fact that fibroblasts secrete VEGF under intermittent hypoxia, and that secreted amounts of VEGF depend on the frequency of the oxygen cycles.¹³³ Intermittent hypoxia has also been applied to investigate pancreatic islet physiology, in the view of improving their transplantation. For this, spheroidal aggregates of pancreatic endocrine cells were exposed to controllable levels of oxygen and glucose,¹²⁴ revealing that pre-conditioning of the pancreatic islets to intermittent

hypoxia increased their steady-state cytoplasmic calcium levels while inhibiting the triggered calcium pulse response that induces insulin secretion upon glucose stimulation.

Physiological barriers and oxygen in organ-on-chips

A subclass of organ-on-chip devices aim to replicate the physiological barriers of the human body, such as the blood-alveolar barrier,^{134,135} the blood-brain barrier,¹³⁶ the intestinal barrier,¹³⁷ etc., typically using a compartmentalized approach with an apical and a basal chamber.¹³⁸ Health-associated bacteria grow under hypoxic conditions, and in fact contribute to them by producing short-chain fatty acids (SCFAs) that stimulate oxidative phosphorylation in gut epithelial cells, whereas disease-associated bacteria do not produce SCFAs and are typically facultative anaerobe, meaning they can also grow under aerobic conditions. A first example, while not being microfluidic, made use of 50 mL culture tubes to establish a co-culture system for investigating the symbiotic relationship between oxygen-requiring intestinal Caco-2 cells and the super oxygen-sensitive health-associated *Faecalibacterium prausnitzii* (*F. prausnitzii*). By varying the oxygen supply through partly opening or fully closing the cap, Sadabad *et al.* observed large differences through analyses of metabolites; Caco-2 cells did not yet show signs of hypoxia after 24 h, indicating there was still sufficient oxygen in the medium.¹³⁹

Recently, a gut microbiome (GuMI) device was developed where the crosstalk between the mucosal barrier of the colon and *F. prausnitzii* could be studied in a long-term culture.¹⁴⁰ The researchers were able to stably establish completely anoxic conditions in the apical side of the GuMI device and aerobic conditions in the basal side. This dual oxygen settings promoted the colon epithelial cells to create a tight barrier and towards a more differentiated state than under static conditions, with a global activation of hypoxia-responsive genes and pathways, despite the aerobic conditions at the basal side (~17% O₂). The presence of flow in the device was crucial for the establishment of the distinct oxygen levels in the two compartments, and creating associated metabolic effects, both in bacteria and colon epithelial cells cultured in the apical compartment. Additionally, the presence of *F. prausnitzii* in the apical side of the device gave rise to anti-inflammatory effects by producing metabolites that help downregulate toll-like receptors 3 and 4 and histone deacetylases, similar to what has been reported *in vivo*. The gut oxygen conditions were also emulated in a two-compartment device separated by a porous membrane.¹⁴¹ Caco-2 cells were grown on the membrane with their basal side facing O₂ flow and the facultative anaerobic bacteria *Escherichia coli* and the anaerobic *Bifidobacterium adolescentis* were added on the apical side. On the top of the device a thick 5 mm extra layer of PDMS was added as a cap to slow down oxygen diffusion. This extra layer, combined with the fast consumption of the oxygen in the medium by the cell monolayer, was shown to



be sufficient to create an anaerobic environment in the side of the device corresponding to the apical side of the Caco-2 cells. As expected, facultative anaerobic bacteria grew at slower rates in the device supplemented with the thick PDMS layer and Caco-2 cell activation of hypoxia markers correlated with a lower oxygen tension in the device. All these examples illustrate the capability and relevance of compartmental control of oxygen conditions in microfluidic devices to study the effect of distinct oxygen levels on the gut microbiome.

Investigation of hypoxia-targeted therapies

As a last example, hypoxia-targeted therapies have been investigated in microfluidic devices with controlled oxygen tension, in the context of cancer. A commonly used chemotherapeutic drug to target cancer cells in a hypoxic microenvironment is tirapazamine (TPZ). TPZ is known to become activated and thus toxic after being reduced in low oxygen environments, which leads to the formation of free radicals and, in turn, DNA damage.¹⁴² This hypoxia-dependent toxicity of TPZ was investigated in an oxygen gradient, revealing an increased sensitivity to TPZ when the oxygen tension diminished.^{93,126} In contrast, a decreased toxicity under low oxygen tension of another, oxygen-dependent chemotherapeutic, bleomycin, was found.

CAR-T cell immunotherapies were influenced by oxygen gradients, with enhanced activity of those CAR-T cells in the normoxic areas of the device and lower cell cytotoxicity in the hypoxic areas.¹²⁵ The decreased activity of the CAR-T cells could be explained by an increase in surface expression of the immunosuppressor molecule PD-L1 by tumour cells linked to HIF-1 α stabilization under hypoxic conditions, or by the competition for glucose specifically under hypoxic conditions. The reduced activity observed in hypoxic regions could help explain why CAR-T cell therapies are more effective in liquid tumours than in solid tumours, which often present large hypoxic regions.

Oxygen control in microfluidic devices: our vision for the future

Over the last years, and as discussed in this review, significant technological/engineering advancements have enhanced our ability to accurately control oxygen levels in *in vitro* models of healthy and/or diseased tissues, which have altogether created a plethora of opportunities for novel or better-designed biological and (bio)medical studies. Reproducing the (patho-)physiological oxygen levels as observed in tissues *in vivo* is always recommended over the commonly used *in vitro* hyperoxic conditions. Cells growing under such conditions may in some instances present oxygen toxicity,² and in other cases reduced cell death.¹²³ It may also simply fail to reflect physiological conditions.¹ Still, given the immense importance of oxygen control, the uptake of experimental approaches that combine physiologically relevant *in vitro* cellular models with engineered systems that

have controllable oxygen conditions is low. In the following, we elaborate on reasons for this and obstacles to be lifted, and we offer our vision of the future, combining both technological and biological aspects, as schematically summarized in Fig. 4.

Technological advances

Arguably, one of the biggest challenges that remain to be addressed is to design technologies and approaches which are more user-friendly, and/or at least easy to implement in non-specialized laboratories. For now, most approaches discussed in this review require both access to dedicated equipment and building complex set-ups, which can represent an obstacle for their massive use by life science or medical researchers. Similarly, engineering challenges concomitantly need to be overcome to make these devices compatible with high-throughput microscopy, which can be achieved by parallelization, automation and increasing modularity. Modularity is of prime importance to create multi-organ-on-a-chip models for studying processes or diseases involving multiple organs or a systemic dimension.¹⁴³ A preferred approach to that end would be to link different platforms representing distinct tissues and not to pursue a body-on-a-chip approach with uniform oxygen levels,¹⁴⁴ since the different models are likely to be maintained at different oxygen levels, as happens in the human body (Fig. 2 and 4). Beyond that, an important next step is the standardization of protocols and devices to support ease of use and wide adoption.¹⁴⁵ Especially for implementation in pharmaceutical settings, massive parallelization and reduction in cost-per-unit is essential. Noteworthy, this challenge is shared with most of the new developments in the fields of microfluidics and organ-on-a-chip technology.^{145–148}

So far, the two engineering aspects of controlling and sensing oxygen levels have been mostly performed separately, or sensing was solely employed as a readout, to notably to calibrate the devices. Yet, coupling these two essential functions, with the incorporation of a feedback loop mechanism to also regulate the oxygen tension in the device could bring another experimental dimension. For instance, as discussed previously, one significant limitation of electrochemical sensors is that they actively consume oxygen, with the risk that the oxygen level in the device progressively deviates from the set value, especially if measurements are continuous. This limitation could be lifted with the implementation of an active regulation mechanism to ensure the oxygen level in the device would remain constant at the desired value, through continuous supplementation or removal of oxygen, *e.g.*, by changing the oxygenation level either of the perfused medium or in the control layers. More importantly, the availability of active regulation would lighten the constraints on the materials used to fabricate the microfluidic devices. If oxygen would diffuse through PDMS, for instance, or any other gas-permeable material, adequate






Fig. 4 Potential elements in next-generation (multi)-organ-on-a-chip devices involving oxygen control. To create next-generation (multi)-organ-on-a-chip devices with an improved ability to mimic physiological conditions in humans, various elements indicated as 'pieces of a puzzle' can be combined in ways that are most suitable to address the research question at hand.

supply of medium with more or less oxygen, depending on the evolution of the system, would compensate once more for any deviation from the initially set oxygen level value. Next-

generation devices combining continuous regulation and real-time sensing can equally benefit biological applications to help unravel possible correlations between oxygen level,



changes therein due to cellular respiration, and disease progression or onset, while possibly maintaining the oxygen level in the device or altering it on-demand.

We focus here on oxygen, as an essential parameter of the cell microenvironment, which is present at different concentrations in different tissues and disease conditions. Yet, the engineering toolbox we discuss in this review could be extended to other important parameters. These include for instance nitrogen, carbon dioxide, and methane, which are all essential for the microbial ecosystem in the human gut microbiome.¹⁴⁹ The pH of the solution represents another key candidate, as acidity, which is tightly linked to the CO₂ level, differs strongly across tissues and between subcellular compartments. Both pH and CO₂ play crucial roles in physiological and pathophysiological situations, including but not limited to lysosomal activities, brain function,¹⁵⁰ tumour tissues,¹⁵¹ cardiovascular diseases as well as serious electrolyte disorders such as metabolic acidosis.¹⁵²

Specific directions that might take hypoxia studies in microfluidic systems to the next level include the incorporation of cells derived from induced pluripotent stem cells (iPSCs) in order to overcome genetic differences between cells (Fig. 4),¹⁵³ and to engineer them to be compatible with novel imaging techniques of 3D tissues like, *e.g.*, light sheet microscopy,¹⁵⁴ optical coherence tomography¹⁵⁵ or wavefront shaping.¹⁵⁶ Especially microscopy techniques that combine real-time information with direct visualisation of the hypoxia response, *e.g.*, using fluorescent fusion proteins with HRE elements in their promoters, would provide more in-depth insights into signalling pathways at the single cell level. Furthermore, analyses have thus far focused mainly on HIF-1 as the main hypoxia-responsive pathway, while there are several more signalling pathways that play crucial roles in determining cellular function, notably involving mTOR and the UPR (Fig. 1 and 4). Molecular analyses of the cells, at the mRNA, protein or secretome levels, would provide complementary information to imaging techniques. Multichannel (cyclical) single molecule FISH (fluorescence *in situ* hybridization) techniques could be used for transcriptome level measurements while retaining the spatial resolution, which is key to correlate gene expression profile and local oxygen abundance.¹⁵⁷ Other approaches that have been developed for off-chip analyses include the determination of the cytokine secretion profile (secretomics)¹⁵⁸ and their metabolic activity using collected medium (metabolomics),¹⁵⁹ or their protein expression profile (proteomics),¹⁶⁰ as well as gene expression analysis or single-cell transcriptomic studies, notably single cell RNA sequencing, after recovery of the cellular materials.¹⁶¹

Innovative applications

The important roles of oxygen and related hypoxia in organ function and disease have now been firmly established. Yet, the existence of many unanswered questions warrants a bright future for innovations in the field of microfluidics and

organ-on-a-chip with respect to better oxygen control. In Table 3, we highlight medical and scientific problems that would greatly benefit from the application of devices with precise oxygen control and possible tight regulation, to generate new fundamental knowledge and provide more appropriate tissue and disease models. Examples include the need for investigations of the interrelationship between autophagy, radiotherapy resistance and hypoxia, the need to better understand the oxygen-dependence of liver metabolism and how drug detoxification is affected by it in the three zones of the liver sinusoid. Furthermore, the replication of the oxygen concentration at different stages of embryo development at the microscale level has the potential to further improve IVF treatments, and investigations on the exposure to intermittent hypoxia in pancreatic islets could provide valuable information regarding the suitability of pancreatic islets for transplantation.

As an illustrative example to highlight where a wider implementation of devices with oxygen control is very likely to benefit research, we will discuss in depth the field of immunotherapy (1st example in Table 3), where new approaches against cancer or infectious diseases are being developed. It has become increasingly evident that the activity of many types of immune cells is profoundly affected by hypoxia. For instance, macrophages massively infiltrate hypoxic regions in a tumour tissue, and remain trapped there, exerting several pro-tumoural functions as tumour-associated macrophages (TAM), including increasing invasion of cancer cells, metastasis and angiogenesis, a multifaceted immunosuppression and resistance to chemotherapy.¹⁶² Hypoxia furthermore attracts neutrophils and promotes their survival by inhibiting apoptosis and inducing glycolytic enzymes in a HIF-1-dependent manner.¹⁶³ There is a striking feed-forward mechanism: neutrophils can further promote hypoxia, which in turn enhances their pro-tumorigenic profile. By relieving hypoxia in tumours, it was shown that neutrophils alter their profile, and become tumouricidal, which altogether leads to a massive reduction in tumour burden.¹⁶⁴ Arguably, these potent effects of oxygen and its regulation have long been underappreciated due to the lack of suitable models at the right oxygen level to study immune cell function. Myeloid-derived suppressor cells (MDSCs) are a further suppressive immune cell type that often accumulates after therapeutic interventions in hypoxic tumour regions; once more, mitigation of hypoxia was reported to block tumour infiltration of MDSCs.¹⁶⁵ Hypoxia also increases the expression of the innate immune checkpoint CD47¹⁶⁶ and the adaptive immune checkpoint PD-L1,^{167,168} which contributes to a reduced potential of immune cells or immune cell-activating therapies to control tumours. While many of these effects are directly mediated by HIF signalling pathways and are therefore likely oxygen-dependent, it is often unclear to what extent the co-occurring acidity in hypoxic tissues could also play a role, as many immunosuppressive effects have also been associated with extracellular acidosis in infections and in solid tumours.¹⁶⁹



Table 3 Opportunities for devices with advanced oxygen control and regulation to address scientific and/or medical problems

Disease/organ/application		What we know	What we do not know
Solid tumours	Immunotherapy resistance	Immune cells exhibit reduced tumour cell-killing activity under hypoxic conditions	What is the (quantitative) relationship between the oxygenation level of tumour tissues and the activity of anti-cancer immunotherapies?
	Radiotherapy resistance	Hypoxic conditions impact the ROS production and thereby therapy effectiveness, and autophagy supports cancer cell survival	How autophagy blockade under hypoxic conditions can be exploited to increase the effectiveness of radiotherapy?
	Metastasis formation	Hypoxia increases the migratory and invasive properties of tumour cells through enhanced EMT	Can hypoxia-targeted anti-tumour drugs reduce EMT and thereby metastasis potential?
Liver	Liver diseases	In non-alcoholic fatty liver disease (NAFLD) there is a differential accumulation of lipids in the different zones of the liver in an oxygen-dependent manner. ^{51–53}	Can the recapitulation of the oxygen gradients together with liver zonation in an <i>in vitro</i> model help to better understand NAFLD (or other liver metabolic diseases) and facilitate the development of new therapies?
	Drug metabolism in liver	(Detoxifying) enzymes are differentially expressed in the three zones of the liver	What is the effect of an oxygen gradient on drug metabolism in the liver?
Brain	<i>In vitro</i> models for neurobiology studies	Brain organoids stop growing when they reach a size of ~4 mm because of poor oxygen diffusion to the core	To what extent is oxygen diffusion a limiting factor in those <i>in vitro</i> models of brain development and function and how could the incorporation of a vasculature-aided oxygen control improve brain organoid size and functionality?
	Stroke	Neurons die when patients suffer from a stroke. Our understanding of the relative contribution of oxygen deprivation and reperfusion injury to neuron toxicity is limited in the context of stroke. Glial cells migrate towards the brain lesion after a stroke, forming a glial scar	Can an <i>in vitro</i> brain-on-a-chip model that simulates the oxygen deprivation and reperfusion help understand the role of oxygen in neuronal death following a stroke? What is the role of oxygen gradients in glial cell migration induced upon a stroke?
<i>In vitro</i> fertilization	Embryo culture for <i>in vitro</i> fertilization	In the oviduct and afterwards in the uterus, embryos grow under hypoxic conditions during their first stages of (pre-implantation) development, but this is not yet standardized in <i>in vitro</i> procedures	Can embryo quality be improved by better emulating the <i>in vivo</i> situation with tight regulation of the oxygen tension during this pre-implantation period?
Fibrosis		Hypoxia has been linked to a variety of fibrotic diseases (e.g., systemic sclerosis, endometriosis)	Does hypoxia have a causal role in the development of fibrotic diseases or is it merely a consequence?
Diabetes	Pancreatic islets transplantation	Exposure to intermittent hypoxia occurs <i>in vivo</i> in pancreatic islets and plays a role in physiology	Does the exposure to microscale-regulated intermittent hypoxia <i>in vitro</i> affect the suitability of pancreatic islets for transplantation?
Gut	Gut microbiome	The composition of the gut microbiome is affected by hypoxia and the presence of oxygen gradients in the gut	How does the oxygen-dependent composition of the gut microbiome affect cancer immunotherapies and inflammation-associated gut disorders?

Furthermore, mTOR signalling is oxygen-dependent and has profound and context-dependent effects on immune function, as illustrated also by the immunosuppressive¹⁷⁰ or immunostimulatory¹⁷¹ effects of the mTOR inhibitor rapamycin at various concentrations in distinct settings. The role and oxygen-dependent activity of mTOR should therefore also be considered when studying immune cell function.

Advanced 3D *in vitro* models can have control over cell density, interstitial flow, and matrix composition as well as the ability to independently control and monitor oxygen levels and acidity. When combined with the visualisation of

cellular processes with a high resolution in real time, this will radically change the way studies are conducted on therapeutic immune cell-metabolic reprogramming approaches as well as (combination) therapies aimed at alleviating the local immunosuppression. Such models have particular promises for the study of nanoparticle-based approaches for targeting hypoxic areas in tumours, which often rely on HIF-1 inhibition or hypoxia-activated prodrugs.¹⁷² Alternatively, these models can be leveraged to investigate the impact of inhibiting the enzymatic activity of carbonic anhydrase IX (CAIX), a HIF-1-inducible protein,



which has the potential to reverse extracellular acidosis under hypoxic conditions.¹⁷³ Since CAIX is highly overexpressed on the surface of tumour cells in hypoxic regions and internalizes very fast by endocytosis,¹⁷⁴ it is an excellent marker and target for the specific delivery of therapeutic or diagnostic agents, *e.g.*, *via* antibodies, nanobodies, or affibodies.^{175–177} Ideally, cellular models that are being exploited for the testing of hypoxia-targeted therapies should have built-in normoxic (tumour) regions in order to properly investigate the selectivity of targeting, the true role of the hypoxia in the observed effect, and to potentially separate these effects from those caused by acidosis to understand if these two parameters could act in a synergistic manner.

Conclusion

Major strides have been made in the design of novel miniaturized devices that support relevant *in vitro* cell culture conditions with physiological or, where this is applicable, pathological oxygen levels. While so far studies have mainly focused on the mere validation of technologies, the field is now ripe for a much broader uptake of advanced cellular models that include oxygen levels as seen in healthy or diseased human tissues, with easy-to-use solutions for non-specialized laboratories being the major hurdle to overcome. Given the multitude of cellular processes that are significantly affected by oxygen levels, our opinion is that down the line, generating appropriate oxygen levels should become a standard feature in essentially all *in vitro* cell and tissue culture studies.

Abbreviations and glossary

ALDOA	Aldolase A – enzyme involved in glucose metabolism (glycolysis)
AMP	Adenosine monophosphate – organic compound that is produced during hydrolysis of high-energy phosphate bonds, notably ATP
AMPK	Adenosine monophosphate-activated protein kinase – central energy sensor that stimulates ATP-producing pathways, and senses AMP
n/a	Angiogenic factors – proteins that stimulate new blood vessel formation (angiogenesis)
ATF6	Activating transcription factor 6 – stress-responsive protein that mediates the UPR
ATP	Adenosine triphosphate – the cell's 'energy currency': organic compound that provides energy to drive cellular processes
ARNT	Aryl hydrocarbon nuclear translocator – constitutively expressed β -subunit of the HIF-1 transcription factor
BiP	Binding immunoglobulin protein – another name for GRP78

CAIX	Carbonic anhydrase IX – downstream target of HIF-1 that catalyzes the interconversion between carbon dioxide and water and the dissociated ions of carbonic acid (bicarbonate and hydrogen ions)
CAR-T cell	Chimeric antigen receptor T cell – genetically engineered T cell for use in immunotherapy
c-MYC	MYC proto-oncogene – proto-oncogene involved in cell division, differentiation, and death
EMT	Epithelial-to-mesenchymal transition – a transcription factor-driven process by which epithelial (tumour) cells lose their cell polarity and cell–cell adhesion properties and become more migratory and invasive
ER	Endoplasmic reticulum – type of cellular organelle composed of a network of tubular membranes that is involved in the transport of molecules
GLUT1	Glucose transporter 1 – protein that facilitates cellular glucose import
n/a	Glutathione – tripeptide antioxidant that prevents damage caused by reactive oxygen species (ROS)
GRP78	Glucose-regulated protein 78 – protein located in the ER involved in proper protein folding and stability
GTPase	Enzyme class that hydrolyses the nucleotide guanosine triphosphate (GTP) to guanosine diphosphate (GDP)
n/a	GTPase Rheb – GTPase that activates mTOR
HIFs	Hypoxia inducible factors – transcription factors involved in the cellular response to hypoxia
HK1	Hexokinase 1 – enzyme involved in glucose metabolism (glycolysis)
HREs	HIF-responsive elements – binding sites for HIFs in the DNA that activate HIF-responsive genes
n/a	Immune evasion – a strategy used by tumours or pathogens to avoid recognition, attack and/or removal by the host's immune system
IRE1	Inositol-requiring enzyme 1 – stress-responsive protein that mediates the UPR
n/a	Liver sinusoid – type of capillary where oxygen-rich blood is mixed with nutrient-rich blood
LDHA	Lactate dehydrogenase A – downstream target of HIF-1 that is involved in energy metabolism
MDSC	Myeloid-derived suppressor cells – immune cell type that contributes to the resistance to cancer (immuno) therapies
n/a	<i>MKI67</i> – gene encoding for protein Ki-67, one of the most used cell proliferation markers
mTOR	Mammalian target of rapamycin – central nutrient sensor that stimulates protein synthesis, growth, and survival



NANOG	Homeobox protein NANOG – transcriptional factor involved in stem cell behaviour. Name derives from the Irish “Tír na nÓg” – land of the young
OCT4	Octamer-binding transcription factor 4 – transcription factor involved in stem cell behaviour
ODD	Oxygen-dependent degradation domain – domain of HIFs that is hydroxylated (addition of an –OH group) at a proline residue and that regulates HIF degradation
PD-L1	Programmed death-ligand 1 – protein involved in suppressing the adaptive arm of the immune system and a target for cancer immunotherapies
PERK	Protein kinase R (PKR)-like endoplasmic reticulum kinase – stress-responsive protein that mediates the UPR
PHD	Prolyl hydroxylase domain protein – protein that hydroxylate (adds an –OH group) HIFs at their ODD
PKM	Pyruvate kinase muscle isozyme – enzyme involved in glucose metabolism (glycolysis)
PTM	Post-translational modification – addition of chemical moieties to proteins after their biosynthesis at the ribosomes
n/a	Proteasome – a waste-disposal nanomachine present inside every cell
ROS	Reactive oxygen species – highly reactive molecules that are involved in cellular signalling but that can cause macromolecular damage when produced in excess
TIA	Transient ischemic attack – temporary neurological dysfunction caused by impeded blood flow without ensuing cell death
TAM	Tumour-associated macrophage – macrophage subtype that is associated with tumours and has a pro-tumorigenic character
UPR	Unfolded protein response – metabolic pathway activated upon endoplasmic reticulum (ER) stress to promote cell survival
TSC1–TSC2	Tuberous sclerosis complex 1–2 – key negative regulator of mTOR, which thereby reduces cellular growth
VE-cadherin	Vascular endothelial cadherin – protein responsible for endothelial cell adhesion
VEGF	Vascular endothelial growth factor – signalling protein that stimulates the growth of new blood vessels
VHL E3	Von Hippel–Lindau E3 – ubiquitin ligase – enzyme that attaches ubiquitin (small regulatory protein) to proteins to prime them for degradation

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

V. P.-C. was supported through an internal funding programme at the Radboud University Medical Center awarded to W. P. R. V. W. P. R. V. and S. L. G. acknowledge financial support from a TURBO (Twente University – RadBOudUMC) grant. S. L. G. acknowledges financial support from the CHIP-ME project (Cross-organ Human *In Vitro* Platforms for Metastatic Environments) funded by Health Holland (project TKI-LSH LSHM19012). We would like to thank Dr. Bastien Venzac for carefully reading the manuscript and providing valuable feedback.

References

- 1 A. Al-Ani, D. Toms, D. Kondro, J. Thundathil, Y. Yu and M. Ungrin, *PLoS One*, 2018, **13**, e0204269.
- 2 D. Lloyd and C. F. Williams, *Adv. Microb. Physiol.*, 2015, **67**, 293–314.
- 3 B. Muz, P. de la Puente, F. Azab and A. K. Azab, *Hypoxia*, 2015, **3**, 83–92.
- 4 C. Beyer, G. Schett, S. Gay, O. Distler and J. H. Distler, *Arthritis Res. Ther.*, 2009, **11**, 220.
- 5 M. Takasawa, J. S. Beech, T. D. Fryer, Y. T. Hong, J. L. Hughes, K. Igase, P. S. Jones, R. Smith, F. I. Aigbirhio, D. K. Menon, J. C. Clark and J. C. Baron, *J. Cereb. Blood Flow Metab.*, 2007, **27**, 679–689.
- 6 A. Valencia and J. H. Burgess, *Circulation*, 1969, **40**, 641–652.
- 7 S. Chouaib, M. Z. Noman, K. Kosmatopoulos and M. A. Curran, *Oncogene*, 2017, **36**, 439–445.
- 8 A. Sharma, J. F. Arambula, S. Koo, R. Kumar, H. Singh, J. L. Sessler and J. S. Kim, *Chem. Soc. Rev.*, 2019, **48**, 771–813.
- 9 S. L. Dunwoodie, *Dev. Cell*, 2009, **17**, 755–773.
- 10 J. E. Lafont, *Int. J. Exp. Pathol.*, 2010, **91**, 99–106.
- 11 W. X. Hong, M. S. Hu, M. Esquivel, G. Y. Liang, R. C. Rennert, A. McArdle, K. J. Paik, D. Duscher, G. C. Gurtner, H. P. Lorenz and M. T. Longaker, *Adv. Wound Care*, 2014, **3**, 390–399.
- 12 T. Kumar, R. Pandey and N. S. Chauhan, *Front. Cell. Infect. Microbiol.*, 2020, **10**, 227.
- 13 C. Jensen and Y. Teng, *Front. Mol. Biosci.*, 2020, **7**, 33.
- 14 W. M. S. Russell and R. L. Burch, *The principles of humane experimental technique*, Methuen, London, 1959.
- 15 R. C. Hubrecht and E. Carter, *Animals*, 2019, **9**, 754.
- 16 N. P. Fenwick and D. Fraser, *Anim. Welfare*, 2005, **14**, 367–377.
- 17 D. G. Hackam and D. A. Redelmeier, *JAMA*, 2006, **296**, 1731–1732.
- 18 B. Fischer and B. D. Bavister, *J. Reprod. Fertil.*, 1993, **99**, 673–679.
- 19 L. H. Gray and J. M. Steadman, *J. Physiol.*, 1964, **175**, 161–171.



- 20 S. N. Bhatia and D. E. Ingber, *Nat. Biotechnol.*, 2014, **32**, 760–772.
- 21 E. W. Young and D. J. Beebe, *Chem. Soc. Rev.*, 2010, **39**, 1036–1048.
- 22 G. M. Whitesides, *Nature*, 2006, **442**, 368–373.
- 23 X. Wang, Z. M. Liu and Y. Pang, *RSC Adv.*, 2017, **7**, 29966–29984.
- 24 E. K. Sackmann, A. L. Fulton and D. J. Beebe, *Nature*, 2014, **507**, 181–189.
- 25 B. G. Wouters and M. Koritzinsky, *Nat. Rev. Cancer*, 2008, **8**, 851–864.
- 26 M. Miranda-Galvis and Y. Teng, *Int. J. Mol. Sci.*, 2020, **21**, 5487.
- 27 P. H. Maxwell, M. S. Wiesener, G. W. Chang, S. C. Clifford, E. C. Vaux, M. E. Cockman, C. C. Wykoff, C. W. Pugh, E. R. Maher and P. J. Ratcliffe, *Nature*, 1999, **399**, 271–275.
- 28 J. Fandrey, T. A. Gorr and M. Gassmann, *Cardiovasc. Res.*, 2006, **71**, 642–651.
- 29 J. Pouyssegur, F. Dayan and N. M. Mazure, *Nature*, 2006, **441**, 437–443.
- 30 J. P. Schöning, M. Monteiro and W. Gu, *Clin. Exp. Pharmacol. Physiol.*, 2017, **44**, 153–161.
- 31 S. L. Yang, C. Wu, Z. F. Xiong and X. Fang, *Mol. Med. Rep.*, 2015, **12**, 2411–2416.
- 32 M. Y. Koh and G. Powis, *Trends Biochem. Sci.*, 2012, **37**, 364–372.
- 33 G. L. Semenza, *Curr. Opin. Genet. Dev.*, 2010, **20**, 51–56.
- 34 J. Jiang, Y. L. Tang and X. H. Liang, *Cancer Biol. Ther.*, 2011, **11**, 714–723.
- 35 H. S. Leong and A. F. Chambers, *Proc. Natl. Acad. Sci. U. S. A.*, 2014, **111**, 887–888.
- 36 P. Vaupel and G. Multhoff, *Adv. Exp. Med. Biol.*, 2018, **1072**, 171–175.
- 37 S. Chipurupalli, E. Kannan, V. Tergaonkar, R. D'Andrea and N. Robinson, *Int. J. Mol. Sci.*, 2019, **20**, 749.
- 38 M. Koritzinsky, F. Levitin, T. van den Beucken, R. A. Rumantir, N. J. Harding, K. C. Chu, P. C. Boutros, I. Braakman and B. G. Wouters, *J. Cell Biol.*, 2013, **203**, 615–627.
- 39 A. S. Lee, *Methods*, 2005, **35**, 373–381.
- 40 K. Lee, W. Tirasophon, X. Shen, M. Michalak, R. Prywes, T. Okada, H. Yoshida, K. Mori and R. J. Kaufman, *Genes Dev.*, 2002, **16**, 452–466.
- 41 L. Romero-Ramirez, H. Cao, D. Nelson, E. Hammond, A. H. Lee, H. Yoshida, K. Mori, L. H. Glimcher, N. C. Denko, A. J. Giaccia, Q. T. Le and A. C. Koong, *Cancer Res.*, 2004, **64**, 5943–5947.
- 42 H. P. Harding, I. Novoa, Y. Zhang, H. Zeng, R. Wek, M. Schapira and D. Ron, *Mol. Cell*, 2000, **6**, 1099–1108.
- 43 J. Wu, D. T. Rutkowski, M. Dubois, J. Swathirajan, T. Saunders, J. Wang, B. Song, G. D. Yau and R. J. Kaufman, *Dev. Cell*, 2007, **13**, 351–364.
- 44 H. Yoshida, T. Matsui, A. Yamamoto, T. Okada and K. Mori, *Cell*, 2001, **107**, 881–891.
- 45 D. M. Sabatini, *Proc. Natl. Acad. Sci. U. S. A.*, 2017, **114**, 11818–11825.
- 46 L. Liu, T. P. Cash, R. G. Jones, B. Keith, C. B. Thompson and M. C. Simon, *Mol. Cell*, 2006, **21**, 521–531.
- 47 Y. Li, K. Inoki and K. L. Guan, *Mol. Cell. Biol.*, 2004, **24**, 7965–7975.
- 48 E. Ortiz-Prado, J. F. Dunn, J. Vasconez, D. Castillo and G. Viscor, *Am. J. Blood Res.*, 2019, **9**, 1–14.
- 49 J. Cervos-Navarro and N. H. Diemer, *Crit. Rev. Neurobiol.*, 1991, **6**, 149–182.
- 50 X. Qian, H. Song and G. L. Ming, *Development*, 2019, **146**, 166074.
- 51 C. Fang, K. O. Lindros, T. M. Badger, M. J. Ronis and M. Ingelman-Sundberg, *Hepatology*, 1998, **27**, 1304–1310.
- 52 K. Jungermann and T. Kietzmann, *Hepatology*, 2000, **31**, 255–260.
- 53 T. Kietzmann, *Redox Biol.*, 2017, **11**, 622–630.
- 54 E. Kasterstein, D. Strassburger, D. Komarovskiy, O. Bern, A. Komsky, A. Raziell, S. Friedler and R. Ron-El, *J. Assist. Reprod. Genet.*, 2013, **30**, 1073–1079.
- 55 J. C. Dumoulin, C. J. Meijers, M. Bras, E. Coonen, J. P. Geraedts and J. L. Evers, *Hum. Reprod.*, 1999, **14**, 465–469.
- 56 I. R. Botusan, V. G. Sunkari, O. Savu, A. I. Catrina, J. Grunler, S. Lindberg, T. Pereira, S. Yla-Herttuala, L. Poellinger, K. Brismar and S. B. Catrina, *Proc. Natl. Acad. Sci. U. S. A.*, 2008, **105**, 19426–19431.
- 57 J. Morand, C. Arnaud, J. L. Pepin and D. Godin-Ribuot, *Sci. Rep.*, 2018, **8**, 2997.
- 58 E. A. Triantafyllou, I. Mylonis, G. Simos and E. Paraskeva, *Hypoxia*, 2019, **7**, 87–91.
- 59 Y. Romero and A. Aquino-Galvez, *Int. J. Mol. Sci.*, 2021, **22**, 8335.
- 60 G. Mehta, A. Y. Hsiao, M. Ingram, G. D. Luker and S. Takayama, *J. Controlled Release*, 2012, **164**, 192–204.
- 61 K. L. Eales, K. E. Hollinshead and D. A. Tennant, *Oncogenesis*, 2016, **5**, e190.
- 62 G. L. Semenza, *Crit. Rev. Biochem. Mol. Biol.*, 2000, **35**, 71–103.
- 63 T. L. Clanton, *J. Appl. Physiol.*, 2007, **102**, 2379–2388.
- 64 J. W. DiGiacomo and D. M. Gilkes, *Target. Oncol.*, 2018, **13**, 157–173.
- 65 W. Luo and Y. Wang, *Adv. Exp. Med. Biol.*, 2019, **1136**, 1–18.
- 66 S. Terry, A. S. T. Engelsens, S. Buart, W. S. Elsayed, G. H. Venkatesh and S. Chouaib, *Cancer Lett.*, 2020, **492**, 1–10.
- 67 M. Hockel and P. Vaupel, *J. Natl. Cancer Inst.*, 2001, **93**, 266–276.
- 68 K. Saxena and M. K. Jolly, *Biomolecules*, 2019, **9**, 339.
- 69 C. Michiels, C. Tellier and O. Feron, *Biochim. Biophys. Acta*, 2016, **1866**, 76–86.
- 70 M. D. Brennan, M. L. Rexius-Hall, L. J. Elgass and D. T. Eddington, *Lab Chip*, 2014, **14**, 4305–4318.
- 71 P. E. Oomen, M. D. Skolimowski and E. Verpoorte, *Lab Chip*, 2016, **16**, 3394–3414.
- 72 K. R. Rivera, M. A. Yokus, P. D. Erb, V. A. Pozdin and M. Daniele, *Analyst*, 2019, **144**, 3190–3215.
- 73 S. G. Charati and S. A. Stern, *Macromolecules*, 1998, **31**, 5529–5535.



- 74 B. Harink, S. Le Gac, D. Barata, C. van Blitterswijk and P. Habibovic, *Lab Chip*, 2014, **14**, 1816–1820.
- 75 J. M. Ayuso, R. Mongel, G. A. Llamazares, M. Moreno, M. Agirregabiria, J. Bergamo, M. Doblare, L. Ochoa and L. J. Fernandez, *Front. Mater.*, 2015, **2**, 37.
- 76 M. Virumbrales-Munoz, J. M. Ayuso, M. Olave, R. Monge, D. de Miguel, L. Martinez-Lostao, S. Le Gac, M. Doblare, I. Ochoa and L. J. Fernandez, *Sci. Rep.*, 2017, **7**, 11998.
- 77 J. M. Ayuso, M. Virumbrales-Munoz, A. Lacueva, P. M. Lanuza, E. Checa-Chavarria, P. Botella, E. Fernandez, M. Doblare, S. J. Allison, R. M. Phillips, J. Pardo, L. J. Fernandez and I. Ochoa, *Sci. Rep.*, 2016, **6**, 36086.
- 78 G. Mehta, J. Lee, W. Cha, Y. C. Tung, J. J. Linderman and S. Takayama, *Anal. Chem.*, 2009, **81**, 3714–3722.
- 79 V. Palacio-Castañeda, L. Kooijman, B. Venzac, W. P. R. Verdurmen and S. Le Gac, *Micromachines*, 2020, **11**, 382.
- 80 J. J. F. Sleeboom, J. Toonder and C. M. Sahlgren, *Int. J. Mol. Sci.*, 2018, **19**, 3047.
- 81 R. Koens, Y. Tabata, J. C. Serrano, S. Aratake, D. Yoshino, R. D. Kamm and K. Funamoto, *APL Bioeng.*, 2020, **4**, 016106.
- 82 K. Funamoto, I. K. Zervantonakis, Y. Liu, C. J. Ochs, C. Kim and R. D. Kamm, *Lab Chip*, 2012, **12**, 4855–4863.
- 83 S. M. Grist, S. S. Nasser, L. Laplatine, J. C. Schmok, D. Yao, J. Hua, L. Chrostowski and K. C. Cheung, *Sci. Rep.*, 2019, **9**, 17782.
- 84 S. M. Grist, J. C. Schmok, M. C. Liu, L. Chrostowski and K. C. Cheung, *Sensors*, 2015, **15**, 20030–20052.
- 85 S. F. Lam, V. S. Shirure, Y. E. Chu, A. G. Soetikno and S. C. George, *PLoS One*, 2018, **13**, e0209574.
- 86 F. T. Lee-Montiel, S. M. George, A. H. Gough, A. D. Sharma, J. Wu, R. DeBiasio, L. A. Verneti and D. L. Taylor, *Exp. Biol. Med.*, 2017, **242**, 1617–1632.
- 87 M. A. Acosta, X. Jiang, P. K. Huang, K. B. Cutler, C. S. Grant, G. M. Walker and M. P. Gamcsik, *Biomicrofluidics*, 2014, **8**, 054117.
- 88 M. L. Rexius-Hall, J. Rehman and D. T. Eddington, *Integr. Biol.*, 2017, **9**, 742–750.
- 89 M. A. Acosta, X. Jiang, P. K. Huang, K. B. Cutler, C. S. Grant, G. M. Walker and M. P. Gamcsik, *Biomicrofluidics*, 2014, **8**, 054117.
- 90 A. A. Jaeger, C. K. Das, N. Y. Morgan, R. H. Pursley, P. G. McQueen, M. D. Hall, T. J. Pohida and M. M. Gottesman, *Biomaterials*, 2013, **34**, 8301–8313.
- 91 S. Barmaki, V. Jokinen, D. Obermaier, D. Blokhina, M. Korhonen, R. H. A. Ras, J. Vuola, S. Franssila and E. Kankuri, *Acta Biomater.*, 2018, **73**, 167–179.
- 92 B. Bulutoglu, C. Rey-Bedon, Y. B. A. Kang, S. Mert, M. L. Yarmush and O. B. Usta, *Lab Chip*, 2019, **19**, 3022–3031.
- 93 Y. A. Chen, A. D. King, H. C. Shih, C. C. Peng, C. Y. Wu, W. H. Liao and Y. C. Tung, *Lab Chip*, 2011, **11**, 3626–3633.
- 94 W. Sun, Y. Chen, Y. Wang, P. Luo, M. Zhang, H. Zhang and P. Hu, *Analyst*, 2018, **143**, 5431–5437.
- 95 K. Funamoto, D. Yoshino, K. Matsubara, I. K. Zervantonakis, K. Funamoto, M. Nakayama, J. Masamune, Y. Kimura and R. D. Kamm, *Integr. Biol.*, 2017, **9**, 529–538.
- 96 H. Nam, K. Funamoto and J. S. Jeon, *Biomicrofluidics*, 2020, **14**, 044107.
- 97 Y. Tabata, D. Yoshino, K. Funamoto, R. Koens, R. D. Kamm and K. Funamoto, *Integr. Biol.*, 2019, **11**, 26–35.
- 98 C. C. Wu, T. Saito, T. Yasukawa, H. Shiku, H. Abe, H. Hoshi and T. Matsue, *Sens. Actuators, B*, 2007, **125**, 680–687.
- 99 Y. Date, S. Takano, H. Shiku, K. Ino, T. Ito-Sasaki, M. Yokoo, H. Abe and T. Matsue, *Biosens. Bioelectron.*, 2011, **30**, 100–106.
- 100 J. Kieninger, A. Weltin, H. Flamm and G. A. Urban, *Lab Chip*, 2018, **18**, 1274–1291.
- 101 S. M. Grist, L. Chrostowski and K. C. Cheung, *Sensors*, 2010, **10**, 9286–9316.
- 102 C. C. Wu, T. Yasukawa, H. Shiku and T. Matsue, *Sens. Actuators, B*, 2005, **110**, 342–349.
- 103 K. Hiramoto, M. Yasumi, H. Ushio, A. Shunori, K. Ino, H. Shiku and T. Matsue, *Anal. Chem.*, 2017, **89**, 10303–10310.
- 104 F. van Rossem, J. G. Bommer, H. L. de Boer, Y. Abbas, E. de Weerd, A. van den Berg and S. Le Gac, *Sens. Actuators, B*, 2017, **238**, 1008–1016.
- 105 E. Tanumihardja, R. H. Slaats, A. D. van der Meer, R. Passier, W. Olthuis and A. van den Berg, *ACS Sens.*, 2021, **6**, 267–274.
- 106 A. Ruggi, F. W. B. van Leeuwen and A. H. Velders, *Coord. Chem. Rev.*, 2011, **255**, 2542–2554.
- 107 G. Mehta, K. Mehta, D. Sud, J. W. Song, T. Bersano-Begey, N. Futai, Y. S. Heo, M. A. Mycek, J. J. Linderman and S. Takayama, *Biomed. Microdevices*, 2007, **9**, 123–134.
- 108 C. O'Donovan, E. Twomey, J. Alderman, T. Moore and D. Papkovsky, *Lab Chip*, 2006, **6**, 1438–1444.
- 109 K. Q. Jiang, P. C. Thomas, S. P. Forry, D. L. DeVoe and S. R. Raghavan, *Soft Matter*, 2012, **8**, 923–926.
- 110 S. M. Grist, N. Oyunerdene, J. Flueckiger, J. Kim, P. C. Wong, L. Chrostowski and K. C. Cheung, *Analyst*, 2014, **139**, 5718–5727.
- 111 Z. Lin, T. Cherng-Wen, P. Roy and D. Trau, *Lab Chip*, 2009, **9**, 257–262.
- 112 E. C. Jensen, *Anat. Rec.*, 2012, **295**, 2031–2036.
- 113 A. S. M. Virumbrales-Muñoz, R. Monge, J.-M. Ayuso, G. A. Llamazares, I. Ochoa, A. Ruggi, L. Fernández and S. Le Gac, *MicroTAS conference 2016*, Dublin (Ireland), 2016.
- 114 D. Yahara, T. Yoshida, Y. Enokida and E. Takahashi, *Adv. Exp. Med. Biol.*, 2016, **923**, 129–134.
- 115 J. V. Joseph, S. Conroy, K. Pavlov, P. Sontakke, T. Tomar, E. Eggens-Meijer, V. Balasubramanian, M. Wagemakers, W. F. den Dunnen and F. A. Krut, *Cancer Lett.*, 2015, **359**, 107–116.
- 116 H. C. Shih, T. A. Lee, H. M. Wu, P. L. Ko, W. H. Liao and Y. C. Tung, *Sci. Rep.*, 2019, **9**, 8234.
- 117 M. B. Byrne, M. T. Leslie, H. S. Patel, H. R. Gaskins and P. J. A. Kenis, *Biomicrofluidics*, 2017, **11**, 054116.
- 118 D. H. Khan, S. A. Roberts, J. R. Cressman and N. Agrawal, *Sci. Rep.*, 2017, **7**, 13487.
- 119 J. F. Lo, E. Sinkala and D. T. Eddington, *Lab Chip*, 2010, **10**, 2394–2401.
- 120 M. W. Boyce, W. C. Simke, R. M. Kenney and M. R. Lockett, *Anal. Methods*, 2020, **12**, 18–24.



- 121 A. S. Truong and M. R. Lockett, *Analyst*, 2016, **141**, 3874–3882.
- 122 M. L. Rexius-Hall, G. Mauleon, A. B. Malik, J. Rehman and D. T. Eddington, *Lab Chip*, 2014, **14**, 4688–4695.
- 123 L. M. Tiede, E. A. Cook, B. Morsey and H. S. Fox, *Cell Death Dis.*, 2011, **2**, e246.
- 124 J. F. Lo, Y. Wang, A. Blake, G. Yu, T. A. Harvat, H. Jeon, J. Oberholzer and D. T. Eddington, *Anal. Chem.*, 2012, **84**, 1987–1993.
- 125 Y. Ando, E. L. Siegler, H. P. Ta, G. E. Cinay, H. Zhou, K. A. Gorrell, H. Au, B. M. Jarvis, P. Wang and K. Shen, *Adv. Healthcare Mater.*, 2019, **8**, e1900001.
- 126 L. Wang, W. Liu, Y. Wang, J. C. Wang, Q. Tu, R. Liu and J. Wang, *Lab Chip*, 2013, **13**, 695–705.
- 127 J. M. Ayuso, R. Monge, A. Martinez-Gonzalez, M. Virumbrales-Munoz, G. A. Llamazares, J. Berganzo, A. Hernandez-Lain, J. Santolaria, M. Doblare, C. Hubert, J. N. Rich, P. Sanchez-Gomez, V. M. Perez-Garcia, I. Ochoa and L. J. Fernandez, *Neuro-Oncology*, 2017, **19**, 503–513.
- 128 A. Gorlach, E. Y. Dimova, A. Petry, A. Martinez-Ruiz, P. Hernansanz-Agustin, A. P. Rolo, C. M. Palmeira and T. Kietzmann, *Redox Biol.*, 2015, **6**, 372–385.
- 129 R. L. Chen, U. H. Lai, L. L. Zhu, A. Singh, M. Ahmed and N. R. Forsyth, *Front. Cell Dev. Biol.*, 2018, **6**, 132.
- 130 M. Tafani, L. Sansone, F. Limana, T. Arcangeli, E. De Santis, M. Polese, M. Fini and M. A. Russo, *Oxid. Med. Cell. Longevity*, 2016, **2016**, 3907147.
- 131 D. R. Beriault and G. H. Werstuck, *Biochim. Biophys. Acta, Mol. Cell Res.*, 2013, **1833**, 2293–2301.
- 132 Y. Ando, H. P. Ta, D. P. Yen, S. S. Lee, S. Raola and K. Shen, *Sci. Rep.*, 2017, **7**, 15233.
- 133 S. M. Ehsan and S. C. George, *J. Biosci. Bioeng.*, 2015, **120**, 347–350.
- 134 D. Huh, B. D. Matthews, A. Mammoto, M. Montoya-Zavala, H. Y. Hsin and D. E. Ingber, *Science*, 2010, **328**, 1662–1668.
- 135 P. Zamprogno, S. Wuthrich, S. Achenbach, G. Thoma, J. D. Stucki, N. Hobi, N. Schneider-Daum, C. M. Lehr, H. Huwer, T. Geiser, R. A. Schmid and O. T. Guenat, *Commun. Biol.*, 2021, **4**, 168.
- 136 A. Oddo, B. Peng, Z. Tong, Y. Wei, W. Y. Tong, H. Thissen and N. H. Voelcker, *Trends Biotechnol.*, 2019, **37**, 1295–1314.
- 137 A. Bein, W. Shin, S. Jalili-Firoozinezhad, M. H. Park, A. Sontheimer-Phelps, A. Tovaglieri, A. Chalkiadaki, H. J. Kim and D. E. Ingber, *Cell. Mol. Gastroenterol. Hepatol.*, 2018, **5**, 659–668.
- 138 C. Moraes, G. Mehta, S. C. Leshner-Perez and S. Takayama, *Ann. Biomed. Eng.*, 2012, **40**, 1211–1227.
- 139 M. S. Sadabad, J. Z. H. von Martels, M. T. Khan, T. Blokzijl, G. Paglia, G. Dijkstra, H. J. M. Harmsen and K. N. Faber, *Sci. Rep.*, 2015, **5**, 17906.
- 140 J. Zhang, Y. J. Huang, J. Y. Yoon, J. Kemmitt, C. Wright, K. Schneider, P. Sphabmixay, V. Hernandez-Gordillo, S. J. Holcomb, B. Bhushan, G. Rohatgi, K. Benton, D. Carpenter, J. C. Kester, G. Eng, D. T. Breault, O. Yilmaz, M. Taketani, C. A. Voigt, R. L. Carrier, D. L. Trumper and L. G. Griffith, *Med*, 2021, **2**, 74–98 e79.
- 141 C. Wang, T. Dang, J. Baste, A. Anil Joshi and A. Bhushan, *FASEB J.*, 2021, **35**, e21291.
- 142 K. B. Peters and J. M. Brown, *Cancer Res.*, 2002, **62**, 5248–5253.
- 143 N. Picollet-D'hahan, A. Zuchowska, I. Lemeunier and S. Le Gac, *Trends Biotechnol.*, 2021, **39**, 788–810.
- 144 J. H. Sung, Y. I. Wang, N. Narasimhan Sriram, M. Jackson, C. Long, J. J. Hickman and M. L. Shuler, *Anal. Chem.*, 2019, **91**, 330–351.
- 145 Q. Ramadan and M. Zourob, *Biomicrofluidics*, 2020, **14**, 041501.
- 146 D. E. Watson, R. Hunziker and J. P. Wikswo, *Exp. Biol. Med.*, 2017, **242**, 1559–1572.
- 147 Q. R. Wu, J. F. Liu, X. H. Wang, L. Y. Feng, J. B. Wu, X. L. Zhu, W. J. Wen and X. Q. Gong, *Biomed. Eng. Online*, 2020, **19**, 9.
- 148 L. A. Low, C. Mummery, B. R. Berridge, C. P. Austin and D. A. Tagle, *Nat. Rev. Drug Discovery*, 2021, **20**, 345–361.
- 149 P. B. Hylemon, S. C. Harris and J. M. Ridlon, *FEBS Lett.*, 2018, **592**, 2070–2082.
- 150 M. Obara, M. Szeliga and J. Albrecht, *Neurochem. Int.*, 2008, **52**, 905–919.
- 151 X. Zhang, Y. Lin and R. J. Gillies, *J. Nucl. Med.*, 2010, **51**, 1167–1170.
- 152 W. Aoi and Y. Marunaka, *BioMed Res. Int.*, 2014, **2014**, 598986.
- 153 Y. Shi, H. Inoue, J. C. Wu and S. Yamanaka, *Nat. Rev. Drug Discovery*, 2017, **16**, 115–130.
- 154 I. Albert-Smet, A. Marcos-Vidal, J. J. Vaquero, M. Desco, A. Munoz-Barrutia and J. Ripoll, *Front. Neuroanat.*, 2019, **13**, 1.
- 155 J. C. McIntosh, L. Yang, T. Wang, H. Zhou, M. R. Lockett and A. L. Oldenburg, *Biomed. Opt. Express*, 2020, **11**, 3181–3194.
- 156 A. Thendiyammal, G. Osnabrugge, T. Knop and I. M. Vellekoop, *Opt. Lett.*, 2020, **45**, 5101–5104.
- 157 C. L. Xia, J. Fan, G. Emanuel, J. J. Hao and X. W. Zhuang, *Proc. Natl. Acad. Sci. U. S. A.*, 2019, **116**, 19490–19499.
- 158 Y. L. Deng, Y. Zhang, S. Sun, Z. H. Wang, M. J. Wang, B. Q. Yu, D. M. Czajkowsky, B. Y. Liu, Y. Li, W. Wei and Q. H. Shi, *Sci. Rep.*, 2014, **4**, 7499.
- 159 D. A. Ouattara, J. M. Prot, A. Bunesco, M. E. Dumas, B. Elena-Herrmann, E. Leclerc and C. Brochot, *Mol. Biosyst.*, 2012, **8**, 1908–1920.
- 160 I. M. Lazar, N. S. Gulakowski and A. C. Lazar, *Anal. Chem.*, 2020, **92**, 169–182.
- 161 R. J. Kimmerling, G. Lee Szeto, J. W. Li, A. S. Genshaft, S. W. Kazer, K. R. Payer, J. de Riba Borrajo, P. C. Blainey, D. J. Irvine, A. K. Shalek and S. R. Manalis, *Nat. Commun.*, 2016, **7**, 10220.
- 162 A. T. Henze and M. Mazzone, *J. Clin. Invest.*, 2016, **126**, 3672–3679.
- 163 P. Sadiku and S. R. Walmsley, *EMBO Rep.*, 2019, **20**, e47388.
- 164 K. Mahiddine, A. Blaisdell, S. Ma, A. Crequer-Grandhomme, C. A. Lowell and A. Erlebacher, *J. Clin. Invest.*, 2020, **130**, 389–403.



- 165 C. Zhang, D. L. Xia, J. H. Liu, D. Huo, X. Q. Jiang and Y. Hu, *Adv. Funct. Mater.*, 2020, **30**, 2000189.
- 166 H. Zhang, H. Lu, L. Xiang, J. W. Bullen, C. Zhang, D. Samanta, D. M. Gilkes, J. He and G. L. Semenza, *Proc. Natl. Acad. Sci. U. S. A.*, 2015, **112**, E6215–E6223.
- 167 Y. Messai, S. Gad, M. Z. Noman, G. Le Teuff, S. Couve, B. Janji, S. F. Kammerer, N. Rioux-Leclerc, M. Hasmim, S. Ferlicot, V. Baud, A. Mejean, D. R. Mole, S. Richard, A. M. M. Eggermont, L. Albiges, F. Mami-Chouaib, B. Escudier and S. Chouaib, *Eur. Urol.*, 2016, **70**, 623–632.
- 168 I. B. Barsoum, C. A. Smallwood, D. R. Siemens and C. H. Graham, *Cancer Res.*, 2014, **74**, 665–674.
- 169 F. E. Diaz, E. Dantas and J. Geffner, *Mediators Inflammation*, 2018, **2018**, 1218297.
- 170 R. N. Saunders, M. S. Metcalfe and M. L. Nicholson, *Kidney Int.*, 2001, **59**, 3–16.
- 171 J. B. Mannick, M. Morris, H. U. P. Hockey, G. Roma, M. Beibel, K. Kulmatycki, M. Watkins, T. Shavlakadze, W. H. Zhou, D. Quinn, D. J. Glass and L. B. Klickstein, *Sci. Transl. Med.*, 2018, **10**, eaaq1564.
- 172 V. L. Silva and W. T. Al-Jamal, *J. Controlled Release*, 2017, **253**, 82–96.
- 173 Y. Lou, P. C. McDonald, A. Oloumi, S. Chia, C. Ostlund, A. Ahmadi, A. Kyle, U. Auf dem Keller, S. Leung, D. Huntsman, B. Clarke, B. W. Sutherland, D. Waterhouse, M. Bally, C. Roskelley, C. M. Overall, A. Minchinton, F. Pacchiano, F. Carta, A. Scozzafava, N. Touisni, J. Y. Winum, C. T. Supuran and S. Dedhar, *Cancer Res.*, 2011, **71**, 3364–3376.
- 174 E. Bourseau-Guilmain, J. A. Menard, E. Lindqvist, V. Indira Chandran, H. C. Christianson, M. Cerezo Magana, J. Lidfeldt, G. Marko-Varga, C. Welinder and M. Belting, *Nat. Commun.*, 2016, **7**, 11371.
- 175 F. J. Huizing, J. Garousi, J. Lok, G. Franssen, B. A. W. Hoebe, F. Y. Frejd, O. C. Boerman, J. Bussink, V. Tolmachev and S. Heskamp, *Sci. Rep.*, 2019, **9**, 18898.
- 176 H. Honarvar, J. Garousi, E. Gunneriusson, I. Hoiden-Guthenberg, M. Altai, C. Widstrom, V. Tolmachev and F. Y. Frejd, *Int. J. Oncol.*, 2015, **46**, 513–520.
- 177 A. S. van Brussel, A. Adams, S. Oliveira, B. Dorresteijn, M. El Khattabi, J. F. Vermeulen, E. van der Wall, W. P. Mali, P. W. Derksen, P. J. van Diest and P. M. van Bergen En Henegouwen, *Mol. Imaging Biol.*, 2016, **18**, 535–544.

